{"text_format":"3","workbook":"xlsx","n_sheets":69,"sheets":["Cover","CONSOLIDATED BALANCE SHEETS","CONSOLIDATED BALANCE SHEETS (Pa","CONSOLIDATED STATEMENTS OF OPER","CONSOLIDATED STATEMENTS OF STOC","CONSOLIDATED STATEMENTS OF CASH","Organization","Recent Accounting Pronouncement","Fair Value Measurements and Hie","Property, Plant, and Equipment","Intangible Assets","Debt","Net Loss per Share","Redeemable Non-Controlling Inte","Segment Reporting","Capitalization","Variable Interest Entities","Income Taxes","Subsequent Events","Pay vs Performance Disclosure","Insider Trading Arrangements","Significant Accounting Policies","Significant Accounting Polici_2","Fair Value Measurements and H_2","Property and Equipment (Tables)","Intangible Assets (Tables)","Debt (Tables)","Net Loss per Share (Tables)","Redeemable Non-controlling In_2","Segment Reporting (Tables)","Capitalization (Tables)","Variable Interest Entities (Tab","Going Concern and Liquidity (De","Significant Accounting Polici_3","Significant Accounting Polici_4","Significant Accounting Polici_5","Significant Accounting Polici_6","Significant Accounting Polici_7","Fair Value Measurements and H_3","Fair Value Measurements and H_4","Fair Value Measurements and H_5","Property and Equipment - Schedu","Property and Equipment - Narrat","Property and Equipment - Assets","Intangible Assets - Schedule of","Intangible Assets - Narrative (","Debt (Details)","Debt - Repurchase Promissory No","Debt - Term Loan Facility (Deta","Debt - VGS Promissory Note (Det","Debt - VGS Promissory Note (D_2","Net Loss per Share - Schedule o","Net Loss per Share - Schedule_2","Redeemable Non-controlling In_3","Redeemable Non-controlling In_4","Segment Reporting (Details)","Capitalization - Reverse Stock ","Variable Interest Entities - Na","Variable Interest Entities - Ba","Variable Interest Entities - In","Income Taxes- Components of Los","Income Taxes- Components of inc","Income Taxes - Reconciliation o","Income Taxes - Narrative (Detai","Subsequent Events (Details)","Warrants - Public and Private P","Warrants (Details)","Related Parties - Atrio Health ","Related Parties - VGS Promissor"],"read":"whole","date_system":"1900"}

{"sheet":"Cover","index":0,"n_rows":38,"n_cols":3,"rows_kept":38,"merged":[[0,0,1,0]]}
["Cover - shares","3 Months Ended"]
[null,"Mar. 31, 2025","May 01, 2025"]
["Document Type","10-Q"," "]
["Document Period End Date","Mar. 31,  2025"," "]
["Document Transition Report","false"," "]
["Entity File Number","001-40033"," "]
["Entity Registrant Name","P3 Health Partners Inc."," "]
["Entity Incorporation, State or Country Code","DE"," "]
["Entity Tax Identification Number","85-2992794"," "]
["Entity Address, Address Line One","2370 Corporate Circle Suite 300"," "]
["Entity Address, City or Town","Henderson"," "]
["Entity Address, State or Province","NV"," "]
["Entity Address, Postal Zip Code","89074"," "]
["City Area Code","702"," "]
["Local Phone Number","910-3950(Registrant’s telephone number, including area code)"," "]
["Entity Current Reporting Status","Yes"," "]
["Entity Interactive Data Current","Yes"," "]
["Entity Filer Category","Non-accelerated Filer"," "]
["Entity Small Business","true"," "]
["Entity Emerging Growth Company","false"," "]
["Entity Shell Company","false"," "]
["Entity Central Index Key","0001832511"," "]
["Entity Central Index Key","--12-31"," "]
["Current Fiscal Year End Date","2025"," "]
["Document Fiscal Period Focus","Q1"," "]
["Document Fiscal Period Focus","false"," "]
["Document Annual Report","true"," "]
["Class A Common Stock"," "," "]
["Title of 12(b) Security","Class A common stock, par value $0.0001 per share"," "]
["Trading Symbol","PIII"," "]
["Security Exchange Name","NASDAQ"," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":3268093,"d":"3,268,093 "}]
["Warrants"," "," "]
["Title of 12(b) Security","Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $575.00"," "]
["Trading Symbol","PIIIW"," "]
["Security Exchange Name","NASDAQ"," "]
["Class V Common Stock"," "," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":3919924,"d":"3,919,924 "}]

{"sheet":"CONSOLIDATED BALANCE SHEETS","index":1,"n_rows":52,"n_cols":4,"rows_kept":52,"merged":[[0,0,0,1],[50,0,50,2],[51,0,51,2]]}
["CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands",null,"Mar. 31, 2025","Dec. 31, 2024"]
["CURRENT ASSETS:",null," "," "]
["Cash",null,{"v":40082,"d":"$ 40,082"},{"v":38816,"d":"$ 38,816"}]
["Restricted cash",null,{"v":1211,"d":"1,211 "},{"v":5286,"d":"5,286 "}]
["Health plan receivable, net of allowance for credit losses of $150",null,{"v":129350,"d":"129,350 "},{"v":121266,"d":"121,266 "}]
["Clinic fees, insurance and other receivable",null,{"v":5409,"d":"5,409 "},{"v":3947,"d":"3,947 "}]
["Prepaid expenses and other current assets",null,{"v":14980,"d":"14,980 "},{"v":14422,"d":"14,422 "}]
["Total assets",null,{"v":403,"d":"403 "},{"v":403,"d":"403 "}]
["TOTAL CURRENT ASSETS",null,{"v":191435,"d":"191,435 "},{"v":184140,"d":"184,140 "}]
["Property and equipment, net",null,{"v":5308,"d":"5,308 "},{"v":5734,"d":"5,734 "}]
["Intangible assets, net",null,{"v":553889,"d":"553,889 "},{"v":574350,"d":"574,350 "}]
["Other long-term assets",null,{"v":33238,"d":"33,238 "},{"v":19196,"d":"19,196 "}]
["TOTAL ASSETS","[1]",{"v":783870,"d":"783,870 "},{"v":783420,"d":"783,420 "}]
["CURRENT LIABILITIES:",null," "," "]
["Accounts payable",null,{"v":11503,"d":"11,503 "},{"v":8442,"d":"8,442 "}]
["Accrued expenses and other current liabilities",null,{"v":27971,"d":"27,971 "},{"v":29416,"d":"29,416 "}]
["Accrued payroll",null,{"v":3216,"d":"3,216 "},{"v":2722,"d":"2,722 "}]
["Health plan settlements payable",null,{"v":56715,"d":"56,715 "},{"v":55565,"d":"55,565 "}]
["Claims payable",null,{"v":268664,"d":"268,664 "},{"v":255089,"d":"255,089 "}]
["Premium deficiency reserve",null,{"v":60406,"d":"60,406 "},{"v":67368,"d":"67,368 "}]
["Accrued interest",null,{"v":12410,"d":"12,410 "},{"v":12460,"d":"12,460 "}]
["Current portion of long-term debt",null,{"v":65000,"d":"65,000 "},{"v":65000,"d":"65,000 "}]
["Short-term debt",null,{"v":796,"d":"796 "},{"v":0,"d":"0 "}]
["Liabilities held for sale",null,{"v":353,"d":"353 "},{"v":353,"d":"353 "}]
["TOTAL CURRENT LIABILITIES",null,{"v":507034,"d":"507,034 "},{"v":496415,"d":"496,415 "}]
["Other long-term liabilities",null,{"v":31665,"d":"31,665 "},{"v":26001,"d":"26,001 "}]
["Operating lease liability",null,{"v":10981,"d":"10,981 "},{"v":11339,"d":"11,339 "}]
["Warrant liabilities",null,{"v":6990,"d":"6,990 "},{"v":10312,"d":"10,312 "}]
["Long-term debt, net",null,{"v":106121,"d":"106,121 "},{"v":89824,"d":"89,824 "}]
["TOTAL LIABILITIES","[1]",{"v":662791,"d":"662,791 "},{"v":633891,"d":"633,891 "}]
["COMMITMENTS AND CONTINGENCIES",null," "," "]
["MEZZANINE EQUITY:",null," "," "]
["Redeemable non-controlling interest",null,{"v":57829,"d":"57,829 "},{"v":73593,"d":"73,593 "}]
["STOCKHOLDERS’ EQUITY:",null," "," "]
["Additional paid in capital",null,{"v":586923,"d":"586,923 "},{"v":579129,"d":"579,129 "}]
["Accumulated deficit",null,{"v":-523673,"d":"(523,673)"},{"v":-503193,"d":"(503,193)"}]
["TOTAL STOCKHOLDERS’ EQUITY",null,{"v":63250,"d":"63,250 "},{"v":75936,"d":"75,936 "}]
["TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY",null,{"v":783870,"d":"$ 783,870"},{"v":783420,"d":"$ 783,420"}]
["Class A Common Stock",null," "," "]
["MEZZANINE EQUITY:",null," "," "]
["Common stock, shares issued (in shares)",null,{"v":3263000,"d":"3,263,000 "},{"v":3257000,"d":"3,257,000 "}]
["Common stock, shares outstanding (in shares)",null,{"v":3263000,"d":"3,263,000 "},{"v":3257000,"d":"3,257,000 "}]
["STOCKHOLDERS’ EQUITY:",null," "," "]
["Common stock",null,{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]
["Class V Common Stock",null," "," "]
["MEZZANINE EQUITY:",null," "," "]
["Common stock, shares issued (in shares)",null," ",{"v":3919000,"d":"3,919,000 "}]
["Common stock, shares outstanding (in shares)",null," ",{"v":3919000,"d":"3,919,000 "}]
["STOCKHOLDERS’ EQUITY:",null," "," "]
["Common stock",null,{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]
[]
["[1] The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 13 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC’s consolidated VIEs totaling $10.7 million and $9.3 million as of March 31, 2025 and December 31, 2024, respectively, and total liabilities of P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $15.6 million and $14.9 million as of March 31, 2025 and December 31, 2024, respectively. These VIE assets and liabilities do not include $41.1 million and $40.3 million of net amounts due to affiliates as of March 31, 2025 and December 31, 2024, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets."]

{"sheet":"CONSOLIDATED BALANCE SHEETS (Pa","index":2,"n_rows":17,"n_cols":3,"rows_kept":17}
["CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Health plan receivable, allowance for credit loss",{"v":150,"d":"$ 150"},{"v":150,"d":"$ 150"}]
["Related Party"," "," "]
["Accounts payable, other",{"v":41100,"d":"41,100 "},{"v":40300,"d":"40,300 "}]
["VIE"," "," "]
["Assets to settle obligations",{"v":10700,"d":"10,700 "},{"v":9300,"d":"9,300 "}]
["Liabilities without recourse to company assets",{"v":15600,"d":"$ 15,600"},{"v":14900,"d":"$ 14,900"}]
["Class A Common Stock"," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized (in shares)",{"v":800000000,"d":"800,000,000 "},{"v":800000000,"d":"800,000,000 "}]
["Common stock, shares issued (in shares)",{"v":3263000,"d":"3,263,000 "},{"v":3257000,"d":"3,257,000 "}]
["Common stock, shares outstanding (in shares)",{"v":3263000,"d":"3,263,000 "},{"v":3257000,"d":"3,257,000 "}]
["Class V Common Stock"," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized (in shares)",{"v":205000000,"d":"205,000,000 "},{"v":205000000,"d":"205,000,000 "}]
["Common stock, shares issued (in shares)"," ",{"v":3919000,"d":"3,919,000 "}]
["Common stock, shares outstanding (in shares)"," ",{"v":3919000,"d":"3,919,000 "}]

{"sheet":"CONSOLIDATED STATEMENTS OF OPER","index":3,"n_rows":34,"n_cols":3,"rows_kept":34,"merged":[[0,0,1,0],[0,1,0,2]]}
["CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["OPERATING REVENUE:"," "," "]
["TOTAL OPERATING REVENUE",{"v":373225,"d":"$ 373,225"},{"v":388488,"d":"$ 388,488"}]
["OPERATING EXPENSE:"," "," "]
["Medical expense",{"v":372043,"d":"372,043 "},{"v":382057,"d":"382,057 "}]
["Premium deficiency reserve",{"v":-6962,"d":"(6,962)"},{"v":1000,"d":"1,000 "}]
["Corporate, general and administrative expense",{"v":24999,"d":"24,999 "},{"v":27401,"d":"27,401 "}]
["Sales and marketing expense",{"v":181,"d":"181 "},{"v":322,"d":"322 "}]
["Depreciation and amortization",{"v":21052,"d":"21,052 "},{"v":21539,"d":"21,539 "}]
["TOTAL OPERATING EXPENSE",{"v":411313,"d":"411,313 "},{"v":432319,"d":"432,319 "}]
["OPERATING LOSS",{"v":-38088,"d":"(38,088)"},{"v":-43831,"d":"(43,831)"}]
["OTHER INCOME (EXPENSE):"," "," "]
["Interest expense, net",{"v":-8725,"d":"(8,725)"},{"v":-4256,"d":"(4,256)"}]
["Mark-to-market of stock warrants",{"v":3322,"d":"3,322 "},{"v":216,"d":"216 "}]
["Other",{"v":318,"d":"318 "},{"v":337,"d":"337 "}]
["TOTAL OTHER INCOME (EXPENSE)",{"v":-5085,"d":"(5,085)"},{"v":-3703,"d":"(3,703)"}]
["LOSS BEFORE INCOME TAXES",{"v":-43173,"d":"(43,173)"},{"v":-47534,"d":"(47,534)"}]
["INCOME TAX PROVISION (EXPENSE)",{"v":-1073,"d":"(1,073)"},{"v":-2072,"d":"(2,072)"}]
["NET LOSS",{"v":-44246,"d":"(44,246)"},{"v":-49606,"d":"(49,606)"}]
["LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST",{"v":-23766,"d":"(23,766)"},{"v":-30906,"d":"(30,906)"}]
["NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST",{"v":-20480,"d":"$ (20,480)"},{"v":-18700,"d":"$ (18,700)"}]
["NET LOSS PER SHARE (Note 9):"," "," "]
["Basic (in dollars per share)",{"v":-6.28,"d":"$ (6.28)"},{"v":-7.86,"d":"$ (7.86)"}]
["Diluted (in dollars per share)",{"v":-6.28,"d":"$ (6.28)"},{"v":-7.86,"d":"$ (7.86)"}]
["WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):"," "," "]
["Basic (in shares)",{"v":3260,"d":"3,260 "},{"v":2378,"d":"2,378 "}]
["Diluted (in shares)",{"v":3260,"d":"3,260 "},{"v":2378,"d":"2,378 "}]
["Capitated Revenue [Member]"," "," "]
["OPERATING REVENUE:"," "," "]
["TOTAL OPERATING REVENUE",{"v":369517,"d":"$ 369,517"},{"v":384134,"d":"$ 384,134"}]
["Other patient service revenue"," "," "]
["OPERATING REVENUE:"," "," "]
["TOTAL OPERATING REVENUE",{"v":3708,"d":"$ 3,708"},{"v":4354,"d":"$ 4,354"}]

{"sheet":"CONSOLIDATED STATEMENTS OF STOC","index":4,"n_rows":40,"n_cols":10,"rows_kept":40}
["CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY AND MEZZANINE EQUITY - USD ($) $ in Thousands","Total","Class A Common Stock","Class V Common Stock","Redeemable Non-controlling Interest","Common Stock Class A Common Stock","Common Stock Class V Common Stock","Additional Paid in Capital","Additional Paid in Capital Class V Common Stock","Accumulated Deficit"]
["Increase (Decrease) in Stockholders' Equity"," "," "," "," "," "," "," "," "," "]
["Beginning balance",{"v":142130,"d":"$ 142,130"}," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":509474,"d":"$ 509,474"}," ",{"v":-367344,"d":"$ (367,344)"}]
["Beginning balance at Dec. 31, 2023",{"v":291532,"d":"291,532 "}," "," "," "," "," "," "," "," "]
["Increase (Decrease) in Temporary Equity"," "," "," "," "," "," "," "," "," "]
["Net loss"," "," "," ",{"v":-1211,"d":"$ (1,211)"}," "," "," "," "," "]
["Class A common stock warrants issued"," "," "," ",{"v":-20579,"d":"(20,579)"}," "," "," "," "," "]
["Net loss"," "," "," ",{"v":-30906,"d":"(30,906)"}," "," "," "," "," "]
["Ending balance at Mar. 31, 2024"," "," "," ",{"v":238836,"d":"238,836 "}," "," "," "," "," "]
["Beginning balance (in shares) at Dec. 31, 2023"," "," "," "," ",{"v":2331000,"d":"2,331,000 "},{"v":3932000,"d":"3,932,000 "}," "," "," "]
["Increase (Decrease) in Stockholders' Equity"," "," "," "," "," "," "," "," "," "]
["Issuance of Class A common stock upon settlement of RSUs, net of shares withheld for tax (in shares)"," "," "," "," ",{"v":55000,"d":"55,000 "}," "," "," "," "]
["At-the-market sales, net of commission and costs",{"v":-73,"d":"(73)"}," "," "," "," "," ",{"v":-73,"d":"(73)"}," "," "]
["Equity-based compensation"," "," ",{"v":1449,"d":"$ 1,449"}," "," "," "," ",{"v":1449,"d":"$ 1,449"}," "]
["Vesting of Class V common stock awards (in shares)"," "," "," "," "," ",{"v":-2000,"d":"(2,000)"}," "," "," "]
["Exchanges of redeemable non-controlling interests for Class A common stock (in shares)"," "," "," "," ",{"v":2000,"d":"2,000 "}," "," "," "," "]
["Net loss",{"v":1211,"d":"1,211 "}," "," "," "," "," ",{"v":1211,"d":"1,211 "}," "," "]
["Class A common stock warrants issued",{"v":20579,"d":"20,579 "}," "," "," "," "," ",{"v":20579,"d":"20,579 "}," "," "]
["Net loss",{"v":-18700,"d":"(18,700)"}," "," "," "," "," "," "," ",{"v":-18700,"d":"(18,700)"}]
["Ending balance (in shares) at Mar. 31, 2024"," "," "," "," ",{"v":2388000,"d":"2,388,000 "},{"v":3930000,"d":"3,930,000 "}," "," "," "]
["Ending balance at Mar. 31, 2024",{"v":146596,"d":"146,596 "}," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":532640,"d":"532,640 "}," ",{"v":-386044,"d":"(386,044)"}]
["Increase (Decrease) in Stockholders' Equity"," "," "," "," "," "," "," "," "," "]
["Beginning balance",{"v":146596,"d":"146,596 "}," "," "," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "},{"v":532640,"d":"532,640 "}," ",{"v":-386044,"d":"(386,044)"}]
["Beginning balance",{"v":75936,"d":"75,936 "}," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":579129,"d":"579,129 "}," ",{"v":-503193,"d":"(503,193)"}]
["Beginning balance at Dec. 31, 2024"," "," "," ",{"v":73593,"d":"73,593 "}," "," "," "," "," "]
["Increase (Decrease) in Temporary Equity"," "," "," "," "," "," "," "," "," "]
["Net loss"," "," "," ",{"v":8002,"d":"8,002 "}," "," "," "," "," "]
["Net loss"," "," "," ",{"v":-23766,"d":"(23,766)"}," "," "," "," "," "]
["Ending balance at Mar. 31, 2025"," "," "," ",{"v":57829,"d":"$ 57,829"}," "," "," "," "," "]
["Beginning balance (in shares) at Dec. 31, 2024"," ",{"v":3257000,"d":"3,257,000 "},{"v":3919000,"d":"3,919,000 "}," ",{"v":3257000,"d":"3,257,000 "},{"v":3919000,"d":"3,919,000 "}," "," "," "]
["Increase (Decrease) in Stockholders' Equity"," "," "," "," "," "," "," "," "," "]
["Equity-based compensation",{"v":1808,"d":"1,808 "}," "," "," "," "," ",{"v":1808,"d":"1,808 "}," "," "]
["Exchanges of redeemable non-controlling interests for Class A common stock (in shares)"," "," "," "," ",{"v":6000,"d":"6,000 "}," "," "," "," "]
["Net loss",{"v":-8002,"d":"(8,002)"}," "," "," "," "," ",{"v":-8002,"d":"(8,002)"}," "," "]
["Class A common stock warrants issued",{"v":13988,"d":"13,988 "}," "," "," "," "," ",{"v":13988,"d":"13,988 "}," "," "]
["Net loss",{"v":-20480,"d":"(20,480)"}," "," "," "," "," "," "," ",{"v":-20480,"d":"(20,480)"}]
["Ending balance (in shares) at Mar. 31, 2025"," ",{"v":3263000,"d":"3,263,000 "}," "," ",{"v":3263000,"d":"3,263,000 "},{"v":3919000,"d":"3,919,000 "}," "," "," "]
["Ending balance at Mar. 31, 2025",{"v":63250,"d":"63,250 "}," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":586923,"d":"586,923 "}," ",{"v":-523673,"d":"(523,673)"}]
["Increase (Decrease) in Stockholders' Equity"," "," "," "," "," "," "," "," "," "]
["Beginning balance",{"v":63250,"d":"$ 63,250"}," "," "," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"},{"v":586923,"d":"$ 586,923"}," ",{"v":-523673,"d":"$ (523,673)"}]

{"sheet":"CONSOLIDATED STATEMENTS OF CASH","index":5,"n_rows":39,"n_cols":3,"rows_kept":39,"merged":[[0,0,1,0],[0,1,0,2]]}
["CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["CASH FLOWS FROM OPERATING ACTIVITIES:"," "," "]
["Net loss",{"v":-44246,"d":"$ (44,246)"},{"v":-49606,"d":"$ (49,606)"}]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "]
["Depreciation and amortization",{"v":21052,"d":"21,052 "},{"v":21539,"d":"21,539 "}]
["Equity-based compensation",{"v":1808,"d":"1,808 "},{"v":1449,"d":"1,449 "}]
["Amortization of original issue discount and debt issuance costs",{"v":331,"d":"331 "},{"v":-140,"d":"(140)"}]
["Mark-to-market adjustment of stock warrants",{"v":-3322,"d":"(3,322)"},{"v":-216,"d":"(216)"}]
["Premium deficiency reserve",{"v":-6962,"d":"(6,962)"},{"v":1000,"d":"1,000 "}]
["Changes in operating assets and liabilities:"," "," "]
["Health plan receivable",{"v":-8084,"d":"(8,084)"},{"v":-25198,"d":"(25,198)"}]
["Clinic fees, insurance, and other receivable",{"v":-1462,"d":"(1,462)"},{"v":2892,"d":"2,892 "}]
["Prepaid expenses and other current assets",{"v":-558,"d":"(558)"},{"v":-3296,"d":"(3,296)"}]
["Other long-term assets",{"v":-14345,"d":"(14,345)"},{"v":-17,"d":"(17)"}]
["Accounts payable, accrued expenses, and other current liabilities",{"v":1593,"d":"1,593 "},{"v":-5553,"d":"(5,553)"}]
["Accrued payroll",{"v":494,"d":"494 "},{"v":1542,"d":"1,542 "}]
["Health plan settlements payable",{"v":1150,"d":"1,150 "},{"v":-12944,"d":"(12,944)"}]
["Claims payable",{"v":13575,"d":"13,575 "},{"v":44168,"d":"44,168 "}]
["Accrued interest",{"v":5614,"d":"5,614 "},{"v":4387,"d":"4,387 "}]
["Operating lease liability",{"v":-104,"d":"(104)"},{"v":-37,"d":"(37)"}]
["Net cash used in operating activities",{"v":-33466,"d":"(33,466)"},{"v":-20030,"d":"(20,030)"}]
["CASH FLOWS FROM INVESTING ACTIVITIES:"," "," "]
["Net cash provided by (used in) investing activities",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["CASH FLOWS FROM FINANCING ACTIVITIES:"," "," "]
["Proceeds from long-term debt, net of original issue discount",{"v":30000,"d":"30,000 "},{"v":10000,"d":"10,000 "}]
["Payment of debt issuance costs",{"v":-139,"d":"(139)"},{"v":0,"d":"0 "}]
["Proceeds from at-the-market sales, net of offering costs paid",{"v":0,"d":"0 "},{"v":33,"d":"33 "}]
["Payment of tax withholdings upon settlement of restricted stock unit awards",{"v":0,"d":"0 "},{"v":-73,"d":"(73)"}]
["Repayment of short-term and long-term debt",{"v":-341,"d":"(341)"},{"v":-430,"d":"(430)"}]
["Proceeds from short-term debt",{"v":1137,"d":"1,137 "},{"v":1871,"d":"1,871 "}]
["Net cash provided by financing activities",{"v":30657,"d":"30,657 "},{"v":11401,"d":"11,401 "}]
["Net change in cash and restricted cash",{"v":-2809,"d":"(2,809)"},{"v":-8629,"d":"(8,629)"}]
["Cash and restricted cash, beginning of period",{"v":44102,"d":"44,102 "},{"v":40934,"d":"40,934 "}]
["Cash and restricted cash, end of period",{"v":41293,"d":"41,293 "},{"v":32305,"d":"32,305 "}]
["Reconciliation of cash and restricted cash:"," "," "]
["Cash",{"v":40082,"d":"40,082 "}," "]
["Restricted cash",{"v":1211,"d":"1,211 "}," "]
["Total cash and restricted cash",{"v":41293,"d":"$ 41,293"},{"v":32305,"d":"$ 32,305"}]

{"sheet":"Organization","index":6,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Organization","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Organization","Note 1: Organization P3 Health Partners Inc. (“P3”) is a patient-centered and physician-led population health management company and, for accounting purposes, the successor to P3 Health Group Holdings, LLC and its subsidiaries (collectively, “P3 LLC,” and together with P3, the “Company”) after the consummation of a series of business combinations in December 2021 with Foresight Acquisition Corp. (the “Business Combinations”). As the sole manager of P3 LLC, P3 operates and controls all of the business and affairs of P3 LLC and P3’s only assets are equity interests in P3 LLC. P3 LLC was founded on April 12, 2017 and began commercial operations on April 20, 2017 to provide population health management services on an at-risk basis to insurance plans offering medical coverage to Medicare beneficiaries under Medicare Advantage programs. Medicare Advantage (“MA”) programs are insurance products created solely for Medicare beneficiaries. Insurance plans contract directly with the Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare beneficiaries benefits that replace traditional Medicare fee-for-service (“FFS”) coverage. The Company’s contracts with health plans are based on an at-risk shared savings model. Under this model, the Company is financially responsible for the cost of all contractually-covered services provided to members assigned to the Company by health plans in exchange for a fixed monthly “capitation” payment, which is generally a percentage of the payment health plans receive from CMS. Under this arrangement, Medicare beneficiaries generally receive all their healthcare coverage through the Company’s network of employed and affiliated physicians and specialists. The services provided to health plans’ members vary by contract. These may include utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans. In addition to the Company’s contracts with health plans, the Company provides primary healthcare services through its employed physician clinic locations. These primary care clinics are reimbursed for services provided under FFS contracts with various payers and through capitated – per member, per month (“PMPM”) arrangements. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced losses since its inception and had net losses of $44.2 million and $49.6 million for the three months ended March 31, 2025 and 2024, respectively. Such losses were primarily the result of costs incurred in adding new members and adverse claims experience, partly driven by general market conditions for MA plans. The Company anticipates operating losses and negative cash flows to continue for the foreseeable future as it continues to grow membership. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of the U.S. Securities and Exchange Commission (“SEC”) Regulation S-X. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations dealing with interim financial statements. Management believes the accompanying unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of periods presented. The condensed consolidated operating results for the three months ended March 31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025, or for any other future annual or interim period. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and all significant intercompany transactions and balances have been eliminated. The Company periodically evaluates entities for consolidation either through ownership of a majority voting interest, or through means other than voting interest, in accordance with the Variable Interest Entity (“VIE”) accounting model. This evaluation includes a qualitative review of the design of the entity, its organizational structure, including decision making ability and financial agreements, as well as a quantitative review. The Company consolidates a VIE when it has a variable interest that provides it with a controlling financial interest in the VIE, referred to as the primary beneficiary of the VIE. As the sole managing member of P3 LLC, P3 has the right to direct the most significant activities of P3 LLC and the obligation to absorb losses and receive benefits. The rights of the non-managing members of P3 LLC are limited and protective in nature and do not give substantive participation rights over the sole managing member. Accordingly, P3 identifies itself as the primary beneficiary of P3 LLC and began consolidating P3 LLC as of December 3, 2021, the closing date of the Business Combinations (the “Closing Date”), resulting in a non-controlling interest related to the common units of P3 LLC (“Common Units”) held by members other than P3. Additionally, as more fully described in Note 13 “Variable Interest Entities,” P3 LLC is the primary beneficiary of the following physician practices (collectively, the “Network VIEs”): • Kahan, Wakefield, Abdou, PLLC • Bacchus, Wakefield, Kahan, PC • P3 Health Partners Professional Services, P.C. • P3 Medical Group, P.C. • P3 Health Partners California, P.C. (f/k/a Omni IPA Medical Group, Inc.) Comprehensive Loss Comprehensive loss includes net loss to common stockholders as well as other changes in equity that result from transactions and economic events other than those with stockholders. There was no difference between comprehensive loss and net loss to common stockholders for the periods presented. Use of Estimates The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that could affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to allowance for credit losses, revenue recognition, the liability for unpaid claims, equity-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets (including intangibles), fair value of liability classified instruments, and judgments related to deferred income taxes. The Company bases its estimates on the best information available at the time, its experiences, and various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. Significant Accounting Policies A description of the Company’s significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2024. No changes to significant accounting policies have occurred since December 31, 2024. Revenue Recognition In the first quarter of 2025, the Company released a portion of the constraint applied in previous periods with respect to risk adjustment revenue for dates of service in 2024, which resulted in an increase to capitation revenue in the amount of $6.4 million for the three months ended March 31, 2025. The Company categorizes revenue based on various factors such as the nature of contracts as follows: Revenue Type Three Months Ended March 31, 2025 % of Total Three Months Ended March 31, 2024 % of Total (dollars in thousands) Capitated revenue $ 369,517 99.0 % $ 384,134 98.9 % Other patient service revenue: Clinical fees & insurance revenue 992 0.3 1,945 0.5 Care coordination / management fees 2,695 0.7 2,390 0.6 Incentive fees 21 0.0 19 0.0 Total other patient service revenue 3,708 1.0 4,354 1.1 Total revenue $ 373,225 100.0 % $ 388,488 100.0 % During the three months ended March 31, 2025 and 2024, five and four health plan customers, respectively, each accounted for 10% or more of total revenue and collectively comprised 75% and 61% of the Company’s total revenue, respectively. Four and three health plan customers, respectively, each accounted for 10% or more of total health plan receivable as of March 31, 2025 and December 31, 2024."]

{"sheet":"Recent Accounting Pronouncement","index":7,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Recent Accounting Pronouncements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Recent Accounting Pronouncements Adopted"," "]
["Recent Accounting Pronouncements","Note 4: Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”) ASU 2024-03 enhances transparency and decision-usefulness of expense disclosures in response to investors’ requests for more detailed, disaggregated expense information, enabling a clearer understanding of a public business entity’s performance and cost structure. The amendments improve disclosure requirements in financial statement notes for specific expense categories, including inventory purchases, employee compensation, depreciation, amortization, and depletion, as well as qualitative descriptions of other expenses. The amendments are effective for fiscal years beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted and can be applied prospectively or retrospectively at the option of the Company. The Company is evaluating the effect ASU 2024-03 will have on its consolidated financial statements and related disclosures. ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures, in response to investors’ feedback, indicating the need for improved information to assess an entity’s operations, tax risks, and planning opportunities, particularly in understanding exposure to jurisdictional tax changes and their impact on cash flows. The amendments address these concerns by improving income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. Retrospective application is permitted. The Company is evaluating the effect ASU 2023-09 will have on its consolidated financial statements and related disclosures. ASU 2023-06, Disclosure Improvements: Codification Amendments In Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”) ASU 2023-06 clarifies or improves disclosure and presentation requirements on a variety of topics and aligns the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this update should be applied prospectively. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is evaluating the effect ASU 2023-06 will have on its consolidated financial statements and related disclosures."]

{"sheet":"Fair Value Measurements and Hie","index":8,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value Measurements and Hierarchy","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Fair Value Measurements and Hierarchy","Note 5: Fair Value Measurements and Hierarchy Information about the Company’s financial liabilities measured at fair value on a recurring basis is presented below: Level 1 Level 2 Level 3 Total (in thousands) Warrant liability as of March 31, 2025 $ 127 $ — $ 6,863 $ 6,990 Warrant liability as of December 31, 2024 $ 127 $ — $ 10,185 $ 10,312 The key Level 3 weighted average inputs into the option pricing model related to the private placement warrants to purchase Class A common stock were as follows: March 31, 2025 December 31, 2024 Volatility 93.5 % 91.7 % Risk-free interest rate 4.0 % 4.4 % Exercise price $ 0.50 $ 0.50 Expected term 6.0 Years 6.2 years Generally, an increase in the market price of the Company’s shares of common stock, an increase in the volatility of the Company’s shares of common stock, and an increase in the remaining term of the warrants would each result in a directionally similar change in the estimated fair value of the Company’s warrant liabilities. Such changes would increase the associated liability while decreases in these assumptions would decrease the associated liability. An increase in the risk-free interest rate would result in a decrease in the estimated fair value measurement and thus a decrease in the associated liability. The Company has not declared, and does not plan to declare, dividends on its common stock and, as such, there is no change in the estimated fair value of the warrant liabilities due to the dividend assumption. The following table sets forth a summary of changes in the fair value of the Company’s private placement warrants to purchase Class A common stock, which are considered to be Level 3 fair value measurements: Three Months Ended March 31, 2025 2024 (in thousands) Beginning balance $ 10,185 $ 29 Mark-to-market adjustment of stock warrants (3,322) (5) Ending balance $ 6,863 $ 24 The Company recorded gains of $3.3 million and $0.2 million from changes in the fair value of stock warrants for the three months ended March 31, 2025 and 2024, respectively. The book value of cash; clinic fees, insurance receivables, and other receivables; accounts payable; and accrued expenses and other current liabilities approximate fair value because of the short maturity and high liquidity of these instruments."]

{"sheet":"Property, Plant, and Equipment","index":9,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property, Plant, and Equipment","3 Months Ended"]
[null,"Mar. 31, 2024"]
["Property, Plant and Equipment [Abstract]"," "]
["Property and Equipment","Note 6: Property and Equipment The Company’s property and equipment balances consisted of the following: March 31, 2025 December 31, 2024 (in thousands) Leasehold improvements $ 2,391 $ 2,332 Furniture & fixtures 1,066 1,106 Computer equipment & software 7,064 7,060 Medical equipment 1,050 1,082 Software (development in process) 343 343 Vehicles 633 659 Other 32 — 12,579 12,582 Less: accumulated depreciation (7,271) (6,848) Property and equipment, net $ 5,308 $ 5,734 Total depreciation of property and equipment recognized on the condensed consolidated statements of operations was $0.6 million and $0.5 million for the three months ended March 31, 2025 and 2024, respectively. Assets Held for Sale On November 30, 2024, the Company and certain of its subsidiaries (the “Sellers”) entered into an asset purchase agreement with certain entities affiliated with an entity in which Chicago Pacific Founders (“CPF”), the Company’s principal stockholder, has an ownership interest (the “Buyers”), which was amended on December 30, 2024, effective as of December 5, 2024 (as amended, the “Florida Asset Purchase Agreement”). Pursuant to the Florida Asset Purchase Agreement, the Sellers sold to the Buyers all of the assets, clinical and non-clinical, exclusively or primarily used by the Company’s MA-related business operated out of Eagle Park, Florida (the “Florida Assets”). The Company closed on the sale of the remaining Florida assets on May 1, 2025, see Note 15 “Subsequent Events” for additional information. Net assets classified as held for sale for the Company’s remaining Florida operations are summarized as follows: March 31, 2025 December 31, 2024 (in thousands) Assets: Property and equipment, net $ 571 $ 571 Intangible assets, net 7,576 7,576 Other long-term assets 314 314 Accumulated impairment (8,058) (8,058) Total assets $ 403 $ 403 Liabilities: Accrued expenses and other current liabilities $ 56 $ 56 Operating lease liability 297 297 Total liabilities $ 353 $ 353 Net assets $ 50 $ 50 "]

{"sheet":"Intangible Assets","index":10,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Intangible Assets","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Intangible Assets [Abstract]"," "]
["Intangible Assets","Note 7: Intangible Assets Intangible assets, net consisted of the following: March 31, 2025 December 31, 2024 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying (in thousands) Indefinite lived intangible assets: Medical licenses $ 700 $ — $ 700 $ 700 $ — $ 700 Definite lived intangible assets: Customer relationships 671,819 (223,553) 448,266 671,819 (206,951) 464,868 Trademarks 148,635 (50,051) 98,584 148,635 (46,427) 102,208 Payor contracts 4,700 (1,528) 3,172 4,700 (1,410) 3,290 Provider network 4,734 (1,567) 3,167 4,734 (1,450) 3,284 Total $ 830,588 $ (276,699) $ 553,889 $ 830,588 $ (256,238) $ 574,350 Amortization of intangible assets was $20.5 million and $21.0 million during the three months ended March 31, 2025 and 2024, respectively."]

{"sheet":"Debt","index":11,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Debt","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Debt","Note 8: Debt Long-term Debt Long-term debt consisted of the following: March 31, 2025 December 31, 2024 (in thousands) Repurchase promissory note, interest paid at 11.0%, due June 2026 $ 15,000 $ 15,000 Term loan facility, interest paid at 12.0%, due December 2025 65,000 65,000 VGS 1 promissory note, interest paid at 13.5%, due June 2028 38,057 38,057 VGS 2 promissory note, interest paid at 17.5%, due September 2027 25,375 25,375 VGS 3 promissory note, interest paid at 19.5%, due June 2028 25,375 25,375 VGS 4 promissory note, interest paid at 19.5%, due August 2028 30,450 — Long-term debt, gross 199,257 168,807 Less: unamortized debt issuance costs and original issue discount (28,136) (13,983) 171,121 154,824 Less: current portion of long-term debt (65,000) (65,000) Long-term debt, net $ 106,121 $ 89,824 VGS 4 Promissory Note On February 13, 2025, P3 LLC entered into a related party financing transaction with VBC Growth SPV 4, LLC (“VGS 4”), consisting of the issuance by P3 LLC of (i) an unsecured promissory note (the “VGS 4 Promissory Note”) to VGS 4 and (ii) a warrant to purchase 1.4 million shares of the Company’s Class A common stock at an exercise price of $10.34 per share to VGS 4, as adjusted for the reverse stock split. The VGS 4 Promissory Note provides for funding of up to $30.0 million, available for draw by P3 LLC in two tranches, as follows: (i) a first tranche of $15.0 million which was drawn on February 18, 2025, and (ii) a second tranche of $15.0 million which was drawn on March 14, 2025. The VGS 4 Promissory Note matures on August 13, 2028. Interest is payable at 19.5% per annum on a quarterly cycle (in arrears) beginning March 31, 2025. P3 LLC may elect to pay either (1) 8.0% cash interest and 11.5% paid in-kind (“PIK”) interest, or (2) 19.5% PIK interest, provided that payment of cash interest will be permitted only to the extent permitted by the Term Loan Agreement (entered into in November 2020 with CRG Servicing, LLC (as amended, the “Term Loan Agreement”) providing for funding of up to $100.0 million (the “Term Loan Facility”)) and the VGS 4 Subordination Agreement (defined below), and if not so permitted, such interest shall accrue as PIK interest. Accrued PIK interest is included in other long-term liabilities in the Company’s condensed consolidated balance sheets. The VGS 4 Promissory Note provides for mandatory prepayments with the proceeds of certain asset sales, and VGS 4 has the right to demand payment in full upon (i) a change of control of the Company and (ii) certain qualified financings (as defined in the VGS 4 Promissory Note). The VGS 4 Promissory Note restricts P3 LLC’s ability and the ability of its subsidiaries to, among other things, incur indebtedness and liens, and make investments and restricted payments. The maturity date may be accelerated as a remedy under certain default provisions in the agreement, or in the event a mandatory prepayment event occurs. P3 LLC paid VGS 4 an up-front fee of 1.5% of the aggregate principal amount of the loan in-kind. In addition, P3 LLC will pay VGS 4 a back-end fee at the time the VGS 4 Promissory Note is redeemed as follows: (i) if paid prior to March 31, 2025, 2.25%; (ii) if paid after March 31, 2025 and on or before June 30, 2025, 4.50%; (iii) if paid after June 30, 2025 and on or before September 30, 2025, 6.75% and (iv) if paid after December 31, 2025, 9.00%. Total debt issuance costs and original issue discount incurred as part of this financing was $14.5 million, which included $14.0 million related to the fair value of the warrant. As of March 31, 2025, unamortized debt issuance costs and original issue discount of $14.2 million related to this financing. VGS 4 Subordination Agreement In connection with the transactions described above, P3 LLC entered into a subordination agreement, dated as of February 13, 2025 (the “VGS 4 Subordination Agreement”), by and among the Company, CRG Servicing LLC (“CRG”), as administrative agent under the Term Loan Facility, and VGS 4. Pursuant to the VGS 4 Subordination Agreement, VGS 4 agreed to subordinate its right of payment under the VGS 4 Promissory Note to the right of payment and security interests of the lenders under the Term Loan Facility. The terms of the VGS 4 Subordination Agreement will effectively require P3 LLC to pay all interest under the VGS 4 Promissory Note in-kind. Amendment to Term Loan Agreement and Consent In connection with the transactions described above, P3 LLC entered into (1) the Seventh Amendment to Term Loan Agreement (the “Term Loan Amendment”), dated as of February 13, 2025, by and among P3 LLC, as borrower, the subsidiary guarantors party thereto, the lenders from time to time party thereto and CRG, as administrative agent and collateral agent and (2) the Consent (the “Consent”), dated as of February 13, 2025, by and between P3 LLC, as borrower, and VBC Growth SPV, LLC (“VGS”), as holder. The Term Loan Amendment and Consent collectively permit the issuance of the VGS 4 Promissory Note and the entry into the VGS 4 Subordination Agreement by P3 LLC."]

{"sheet":"Net Loss per Share","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Net Loss per Share","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Net Loss per Share","Note 9: Net Loss per Share The following table provides the computation of basic and diluted net loss per share: Three Months Ended March 31, 2025 2024 (in thousands, except per share data) Numerator–basic: Net loss attributable to Class A common stockholders–basic $ (20,480) $ (18,700) Numerator–diluted: Net loss attributable to Class A common stockholders–basic $ (20,480) $ (18,700) Effective of dilutive securities: Shares of Class V common stock — — Net loss attributable to Class A common stockholders–diluted $ (20,480) $ (18,700) Denominator–basic: Weighted average Class A common shares outstanding–basic 3,260 2,378 Net loss per share attributable to Class A common stockholders–basic $ (6.28) $ (7.86) Denominator–diluted: Weighted average Class A common shares outstanding–basic 3,260 2,378 Weighted average effect of dilutive securities: Shares of Class V common stock — — Weighted average shares outstanding–diluted 3,260 2,378 Net loss per share attributable to Class A common stockholders–diluted $ (6.28) $ (7.86) All periods presented in the table above have been retroactively adjusted to reflect the 1-for-50 reverse stock split effected on April 11, 2025. See Note 3 “Significant Accounting Policies” for further information. Shares of Class V common stock do not share in the earnings or losses of P3 and are therefore not participating securities. As such, separate presentation of basic and diluted net loss per share for Class V common stock under the two-class method is not required. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive, adjusted for the reverse stock split as noted above. Three Months Ended March 31, 2025 2024 (in thousands) Stock warrants (1) 6,358 1,639 Stock options (1) 433 111 Restricted stock units (1) 141 93 Shares of Class V common stock (2) 3,919 3,930 Total 10,851 5,773 __________________ (1) Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share. (2) Shares of Class V common stock at the end of the period are considered antidilutive shares of Class A common stock under application of the if-converted method in 2024 and 2025."]

{"sheet":"Redeemable Non-Controlling Inte","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Redeemable Non-Controlling Interests","3 Months Ended"]
[null,"Mar. 31, 2024"]
["Noncontrolling Interest [Abstract]"," "]
["Redeemable Non-Controlling Interest","Note 10: Redeemable Non-controlling Interest Non-controlling interest represents the portion of P3 LLC that the Company controls and consolidates but does not own (i.e., the Common Units held directly by equity holders other than the Company). The ownership of the Common Units is summarized as follows: March 31, 2025 December 31, 2024 Units (in thousands) Ownership % Units (in thousands) Ownership % P3 Health Partners Inc. ’ s ownership of Common Units 3,263 45.4 % 3,257 45.4 % Non-controlling interest holders ’ ownership of Common Units 3,919 54.6 3,919 54.6 Total Common Units 7,182 100.0 % 7,176 100.0 % All periods presented in the table above have been retroactively adjusted to reflect the 1-for-50 reverse stock split effected on April 11, 2025. See Note 3 “Significant Accounting Policies” for further information. During the three months ended March 31, 2024, the Company issued an aggregate of 1,500 shares of Class A common stock to P3 LLC members in connection with such members’ redemptions of an equivalent number of Common Units and corresponding cancellation and retirement of an equivalent number of Class V common stock. Such retired shares of Class V common stock may not be reissued. The redemptions occurred pursuant to the terms of the P3 LLC Amended and Restated Limited Liability Company Agreement (the “P3 LLC A&R LLC Agreement”). No similar exchanges or redemptions occurred during the three months ended March 31, 2025."]

{"sheet":"Segment Reporting","index":14,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segment Reporting","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Segment Reporting [Abstract]"," "]
["Segment Reporting","Note 11: Segment Reporting The Company’s operations are organized under one reportable segment. The following tables present information about the Company’s reportable segment: Three Months Ended March 31, 2025 2024 (in thousands) Operating revenue $ 373,225 $ 388,488 Less: Medical claims expense (352,317) (347,582) Other medical expense (1) (19,726) (34,475) Depreciation and amortization (21,052) (21,539) Other segment items (2) (14,900) (28,561) Interest expense, net (8,725) (4,256) Interest income 322 391 Loss before income taxes (43,173) (47,534) Income tax provision (1,073) (2,072) Net loss $ (44,246) $ (49,606) March 31, 2025 December 31, 2024 (in thousands) Segment assets $ 129,350 $ 121,266 __________________ (1) Other medical expense includes subcapitation expense, affiliate provider compensation expense, and other non-claim costs. (2) Other segment items include premium deficiency reserve, corporate, general and administrative expense, sales and marketing expense, and miscellaneous income and expense."]

{"sheet":"Capitalization","index":15,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Capitalization","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Capitalization","Note 12: Capitalization Reverse Stock Split On April 11, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the \"Charter Amendment\") with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split (the \"Reverse Stock Split\") of the Company's outstanding Class A common stock, $0.0001 par value per share, and Class V common stock, $0.0001 par value per share, as of that date. The Reverse Stock Split resulted in 163,159,548 shares of Class A common stock being converted to 3,263,093 shares of Class A common stock and 195,956,984 shares of Class V common stock being converted to 3,919,124 shares of Class V common stock. The Board of Directors of the Company approved the Charter Amendment to meet the share bid price requirements of the Nasdaq Capital Market. The Company’s stockholders approved the Charter Amendment at a special meeting held on March 31, 2025. No fractional shares were issued as a result of the Reverse Stock Split. Each stockholder was entitled to receive a cash payment equal to the fraction of a share to which such stockholder would otherwise have been entitled multiplied by the closing price per share of the Class A common stock as reported by The Nasdaq Capital Market (as adjusted to give effect to the Reverse Stock Split) on the effective date of the Reverse Stock Split. Proportional adjustments were made to the number of shares of Class A common stock underlying the Company’s outstanding equity awards and warrants, as well as the exercise or conversion price, as applicable, and to the number of shares issuable under the Company’s equity incentive plans and other existing agreements. All options and restricted stock awards of the Company outstanding immediately prior to the split have been adjusted in accordance with the terms of the plans, agreements or arrangements governing such options and restricted stock awards. Each stockholder’s percentage ownership interest in the Company and proportional voting power remained unchanged by the split, except for minor changes and adjustments that resulted from the treatment of fractional shares. The "]

{"sheet":"Variable Interest Entities","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Variable Interest Entities","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Variable Interest Entities"," "]
["Variable Interest Entities","Note 13: Variable Interest Entities P3 LLC has Management Services Agreements (“MSAs”) and deficit funding agreements with the Network VIEs. The MSAs provide that P3 LLC will furnish administrative personnel, office supplies and equipment, general business services, contract negotiation, and billing and collection services to the Network VIEs. Fees for these services are the excess of the Network VIEs’ revenue over expenses. Per the deficit funding agreements, P3 LLC is obligated to advance funds, as needed, to support the Network VIEs’ working capital needs to the extent operating expenses exceed gross revenue. These advances accrue interest at a rate of prime P3 LLC, directly or indirectly via its wholly owned subsidiaries, may not use or access any net assets of the Network VIEs to settle its obligations or the obligations of its wholly owned subsidiaries. Additionally, the creditors of the Network VIEs do not have recourse to the net assets of P3 LLC. Since P3 LLC represents substantially all the assets and liabilities of the Company, the following tables provide a summary of the assets, liabilities, and operating performance of only VIEs held at the P3 LLC level. March 31, 2025 December 31, 2024 (in thousands) ASSETS Cash $ 5,093 $ 5,216 Clinic fees, insurance and other receivable 3,012 2,440 Health plan receivable — — Prepaid expenses and other current assets 450 447 Property and equipment, net 32 37 Other long-term assets 2,075 1,116 TOTAL ASSETS $ 10,662 $ 9,256 LIABILITIES AND MEMBERS’ DEFICIT Accounts payable $ 4,319 $ 4,521 Accrued expenses and other current liabilities 1,685 677 Accrued payroll 4,338 3,795 Claims payable 4,456 5,004 Other long-term liabilities 840 919 Due to consolidated entities of P3 41,070 40,264 TOTAL LIABILITIES 56,708 55,180 MEMBERS’ DEFICIT (46,046) (45,924) TOTAL LIABILITIES AND MEMBERS’ DEFICIT $ 10,662 $ 9,256 Three Months Ended March 31, 2025 2024 (in thousands) Revenue $ 8,159 $ 9,764 Expense 8,154 9,897 Net loss $ 5 $ (133)"]

{"sheet":"Income Taxes","index":17,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Income Taxes","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Income Tax Disclosure [Abstract]"," "]
["Income Taxes","Note 14: Income Taxes The Company’s tax rate is affected primarily by the recognition of a valuation allowance and the portion of income and expense allocated to the non-controlling interest. It is also affected by discrete items that may occur in any given year such as benefits from changes in the fair value of private placement and public warrants. During the three months ended March 31, 2025, the Company’s tax rate was impacted by the valuation allowance placed on deferred tax assets in prior periods and state taxes."]

{"sheet":"Subsequent Events","index":18,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Subsequent Events","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Subsequent Events [Abstract]"," "]
["Subsequent Events","Note 15: Subsequent Events Reverse Stock Split On April 11, 2025, the Company effected a 1-for-50 reverse stock split of its Class A common stock and Class V common stock, $0.0001 par value. See Note 12 “Capitalization” included in this Form 10-Q for additional information related to the reverse stock split. Asset sale"]

{"sheet":"Pay vs Performance Disclosure","index":19,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Pay vs Performance Disclosure - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Pay vs Performance Disclosure"," "," "]
["Net Income (Loss) Attributable to Parent",{"v":-20480,"d":"$ (20,480)"},{"v":-18700,"d":"$ (18,700)"}]

{"sheet":"Insider Trading Arrangements","index":20,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Trading Arrangements, by Individual"," "]
["Rule 10b5-1 Arrangement Adopted","false"]
["Non-Rule 10b5-1 Arrangement Adopted","false"]
["Rule 10b5-1 Arrangement Terminated","false"]
["Non-Rule 10b5-1 Arrangement Terminated","false"]

{"sheet":"Significant Accounting Policies","index":21,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Significant Accounting Policies (Policies)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["Recently Adopted Accounting Pronouncements/ Recent Accounting Pronouncements Not Yet Adopted","Recent Accounting Pronouncements Not Yet Adopted ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”) ASU 2024-03 enhances transparency and decision-usefulness of expense disclosures in response to investors’ requests for more detailed, disaggregated expense information, enabling a clearer understanding of a public business entity’s performance and cost structure. The amendments improve disclosure requirements in financial statement notes for specific expense categories, including inventory purchases, employee compensation, depreciation, amortization, and depletion, as well as qualitative descriptions of other expenses. The amendments are effective for fiscal years beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted and can be applied prospectively or retrospectively at the option of the Company. The Company is evaluating the effect ASU 2024-03 will have on its consolidated financial statements and related disclosures. ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures, in response to investors’ feedback, indicating the need for improved information to assess an entity’s operations, tax risks, and planning opportunities, particularly in understanding exposure to jurisdictional tax changes and their impact on cash flows. The amendments address these concerns by improving income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. The amendments in this update are effective for annual periods beginning after December 15, 2024 and should be applied prospectively. Retrospective application is permitted. The Company is evaluating the effect ASU 2023-09 will have on its consolidated financial statements and related disclosures. ASU 2023-06, Disclosure Improvements: Codification Amendments In Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”) ASU 2023-06 clarifies or improves disclosure and presentation requirements on a variety of topics and aligns the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this update should be applied prospectively. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is evaluating the effect ASU 2023-06 will have on its consolidated financial statements and related disclosures."]
["Long-Lived Assets Held-for-Sale","Net assets classified as held for sale for the Company’s remaining Florida operations are summarized as follows: March 31, 2025 December 31, 2024 (in thousands) Assets: Property and equipment, net $ 571 $ 571 Intangible assets, net 7,576 7,576 Other long-term assets 314 314 Accumulated impairment (8,058) (8,058) Total assets $ 403 $ 403 Liabilities: Accrued expenses and other current liabilities $ 56 $ 56 Operating lease liability 297 297 Total liabilities $ 353 $ 353 Net assets $ 50 $ 50 "]

{"sheet":"Significant Accounting Polici_2","index":22,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Significant Accounting Policies (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["Long-Lived Assets Held-for-Sale","Net assets classified as held for sale for the Company’s remaining Florida operations are summarized as follows: March 31, 2025 December 31, 2024 (in thousands) Assets: Property and equipment, net $ 571 $ 571 Intangible assets, net 7,576 7,576 Other long-term assets 314 314 Accumulated impairment (8,058) (8,058) Total assets $ 403 $ 403 Liabilities: Accrued expenses and other current liabilities $ 56 $ 56 Operating lease liability 297 297 Total liabilities $ 353 $ 353 Net assets $ 50 $ 50 "]

{"sheet":"Fair Value Measurements and H_2","index":23,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Fair Value Measurements and Hierarchy (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Schedule of Fair Value Hierarchy for Financial Liabilities","Information about the Company’s financial liabilities measured at fair value on a recurring basis is presented below: Level 1 Level 2 Level 3 Total (in thousands) Warrant liability as of March 31, 2025 $ 127 $ — $ 6,863 $ 6,990 Warrant liability as of December 31, 2024 $ 127 $ — $ 10,185 $ 10,312 "]
["Schedule of Fair Value Measurement Inputs and Valuation Techniques","The key Level 3 weighted average inputs into the option pricing model related to the private placement warrants to purchase Class A common stock were as follows: March 31, 2025 December 31, 2024 Volatility 93.5 % 91.7 % Risk-free interest rate 4.0 % 4.4 % Exercise price $ 0.50 $ 0.50 Expected term 6.0 Years 6.2 years"]
["Schedule of Changes in the Fair Value","The following table sets forth a summary of changes in the fair value of the Company’s private placement warrants to purchase Class A common stock, which are considered to be Level 3 fair value measurements: Three Months Ended March 31, 2025 2024 (in thousands) Beginning balance $ 10,185 $ 29 Mark-to-market adjustment of stock warrants (3,322) (5) Ending balance $ 6,863 $ 24 "]

{"sheet":"Property and Equipment (Tables)","index":24,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Property and Equipment (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Property, Plant and Equipment [Abstract]"," "]
["Schedule of Property and Equipment","The Company’s property and equipment balances consisted of the following: March 31, 2025 December 31, 2024 (in thousands) Leasehold improvements $ 2,391 $ 2,332 Furniture & fixtures 1,066 1,106 Computer equipment & software 7,064 7,060 Medical equipment 1,050 1,082 Software (development in process) 343 343 Vehicles 633 659 Other 32 — 12,579 12,582 Less: accumulated depreciation (7,271) (6,848) Property and equipment, net $ 5,308 $ 5,734 "]
["Long-Lived Assets Held-for-Sale","Net assets classified as held for sale for the Company’s remaining Florida operations are summarized as follows: March 31, 2025 December 31, 2024 (in thousands) Assets: Property and equipment, net $ 571 $ 571 Intangible assets, net 7,576 7,576 Other long-term assets 314 314 Accumulated impairment (8,058) (8,058) Total assets $ 403 $ 403 Liabilities: Accrued expenses and other current liabilities $ 56 $ 56 Operating lease liability 297 297 Total liabilities $ 353 $ 353 Net assets $ 50 $ 50 "]

{"sheet":"Intangible Assets (Tables)","index":25,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Intangible Assets (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Intangible Assets [Abstract]"," "]
["Schedule of Finite-Lived Intangible Assets","Intangible assets, net consisted of the following: March 31, 2025 December 31, 2024 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying (in thousands) Indefinite lived intangible assets: Medical licenses $ 700 $ — $ 700 $ 700 $ — $ 700 Definite lived intangible assets: Customer relationships 671,819 (223,553) 448,266 671,819 (206,951) 464,868 Trademarks 148,635 (50,051) 98,584 148,635 (46,427) 102,208 Payor contracts 4,700 (1,528) 3,172 4,700 (1,410) 3,290 Provider network 4,734 (1,567) 3,167 4,734 (1,450) 3,284 Total $ 830,588 $ (276,699) $ 553,889 $ 830,588 $ (256,238) $ 574,350 "]
["Schedule of Indefinite-Lived Intangible Assets","Intangible assets, net consisted of the following: March 31, 2025 December 31, 2024 Gross Carrying Accumulated Net Carrying Gross Carrying Accumulated Net Carrying (in thousands) Indefinite lived intangible assets: Medical licenses $ 700 $ — $ 700 $ 700 $ — $ 700 Definite lived intangible assets: Customer relationships 671,819 (223,553) 448,266 671,819 (206,951) 464,868 Trademarks 148,635 (50,051) 98,584 148,635 (46,427) 102,208 Payor contracts 4,700 (1,528) 3,172 4,700 (1,410) 3,290 Provider network 4,734 (1,567) 3,167 4,734 (1,450) 3,284 Total $ 830,588 $ (276,699) $ 553,889 $ 830,588 $ (256,238) $ 574,350 "]

{"sheet":"Debt (Tables)","index":26,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Debt (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Schedule of Long-Term Debt","Long-term debt consisted of the following: March 31, 2025 December 31, 2024 (in thousands) Repurchase promissory note, interest paid at 11.0%, due June 2026 $ 15,000 $ 15,000 Term loan facility, interest paid at 12.0%, due December 2025 65,000 65,000 VGS 1 promissory note, interest paid at 13.5%, due June 2028 38,057 38,057 VGS 2 promissory note, interest paid at 17.5%, due September 2027 25,375 25,375 VGS 3 promissory note, interest paid at 19.5%, due June 2028 25,375 25,375 VGS 4 promissory note, interest paid at 19.5%, due August 2028 30,450 — Long-term debt, gross 199,257 168,807 Less: unamortized debt issuance costs and original issue discount (28,136) (13,983) 171,121 154,824 Less: current portion of long-term debt (65,000) (65,000) Long-term debt, net $ 106,121 $ 89,824 "]
["Contractual Obligation, Fiscal Year Maturity"," "]

{"sheet":"Net Loss per Share (Tables)","index":27,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Net Loss per Share (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Schedule of Computation of Basic and Diluted Net Loss Per Share","The following table provides the computation of basic and diluted net loss per share: Three Months Ended March 31, 2025 2024 (in thousands, except per share data) Numerator–basic: Net loss attributable to Class A common stockholders–basic $ (20,480) $ (18,700) Numerator–diluted: Net loss attributable to Class A common stockholders–basic $ (20,480) $ (18,700) Effective of dilutive securities: Shares of Class V common stock — — Net loss attributable to Class A common stockholders–diluted $ (20,480) $ (18,700) Denominator–basic: Weighted average Class A common shares outstanding–basic 3,260 2,378 Net loss per share attributable to Class A common stockholders–basic $ (6.28) $ (7.86) Denominator–diluted: Weighted average Class A common shares outstanding–basic 3,260 2,378 Weighted average effect of dilutive securities: Shares of Class V common stock — — Weighted average shares outstanding–diluted 3,260 2,378 Net loss per share attributable to Class A common stockholders–diluted $ (6.28) $ (7.86)"]
["Schedule of potential dilutive securities excluded from the computation of diluted net loss per share their effect would have been anti-dilutive","The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive, adjusted for the reverse stock split as noted above. Three Months Ended March 31, 2025 2024 (in thousands) Stock warrants (1) 6,358 1,639 Stock options (1) 433 111 Restricted stock units (1) 141 93 Shares of Class V common stock (2) 3,919 3,930 Total 10,851 5,773 __________________ (1) Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net loss per share. (2) Shares of Class V common stock at the end of the period are considered antidilutive shares of Class A common stock under application of the if-converted method in 2024 and 2025."]

{"sheet":"Redeemable Non-controlling In_2","index":28,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Redeemable Non-controlling Interest (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Noncontrolling Interest [Abstract]"," "]
["Schedule of Ownership of Common Units","The ownership of the Common Units is summarized as follows: March 31, 2025 December 31, 2024 Units (in thousands) Ownership % Units (in thousands) Ownership % P3 Health Partners Inc. ’ s ownership of Common Units 3,263 45.4 % 3,257 45.4 % Non-controlling interest holders ’ ownership of Common Units 3,919 54.6 3,919 54.6 Total Common Units 7,182 100.0 % 7,176 100.0 %"]

{"sheet":"Segment Reporting (Tables)","index":29,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Segment Reporting (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Segment Reporting [Abstract]"," "]
["Schedule of Segment Reporting Information, by Segment","The following tables present information about the Company’s reportable segment: Three Months Ended March 31, 2025 2024 (in thousands) Operating revenue $ 373,225 $ 388,488 Less: Medical claims expense (352,317) (347,582) Other medical expense (1) (19,726) (34,475) Depreciation and amortization (21,052) (21,539) Other segment items (2) (14,900) (28,561) Interest expense, net (8,725) (4,256) Interest income 322 391 Loss before income taxes (43,173) (47,534) Income tax provision (1,073) (2,072) Net loss $ (44,246) $ (49,606) March 31, 2025 December 31, 2024 (in thousands) Segment assets $ 129,350 $ 121,266 __________________ (1) Other medical expense includes subcapitation expense, affiliate provider compensation expense, and other non-claim costs. (2) Other segment items include premium deficiency reserve, corporate, general and administrative expense, sales and marketing expense, and miscellaneous income and expense."]

{"sheet":"Capitalization (Tables)","index":30,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Capitalization (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Schedule of Fair Value Measurement Inputs and Valuation Techniques","The key Level 3 weighted average inputs into the option pricing model related to the private placement warrants to purchase Class A common stock were as follows: March 31, 2025 December 31, 2024 Volatility 93.5 % 91.7 % Risk-free interest rate 4.0 % 4.4 % Exercise price $ 0.50 $ 0.50 Expected term 6.0 Years 6.2 years"]

{"sheet":"Variable Interest Entities (Tab","index":31,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Variable Interest Entities (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Variable Interest Entities"," "]
["Summary of balance sheet and income statement of VIEs","Since P3 LLC represents substantially all the assets and liabilities of the Company, the following tables provide a summary of the assets, liabilities, and operating performance of only VIEs held at the P3 LLC level. March 31, 2025 December 31, 2024 (in thousands) ASSETS Cash $ 5,093 $ 5,216 Clinic fees, insurance and other receivable 3,012 2,440 Health plan receivable — — Prepaid expenses and other current assets 450 447 Property and equipment, net 32 37 Other long-term assets 2,075 1,116 TOTAL ASSETS $ 10,662 $ 9,256 LIABILITIES AND MEMBERS’ DEFICIT Accounts payable $ 4,319 $ 4,521 Accrued expenses and other current liabilities 1,685 677 Accrued payroll 4,338 3,795 Claims payable 4,456 5,004 Other long-term liabilities 840 919 Due to consolidated entities of P3 41,070 40,264 TOTAL LIABILITIES 56,708 55,180 MEMBERS’ DEFICIT (46,046) (45,924) TOTAL LIABILITIES AND MEMBERS’ DEFICIT $ 10,662 $ 9,256 Three Months Ended March 31, 2025 2024 (in thousands) Revenue $ 8,159 $ 9,764 Expense 8,154 9,897 Net loss $ 5 $ (133)"]

{"sheet":"Going Concern and Liquidity (De","index":32,"n_rows":6,"n_cols":4,"rows_kept":6,"merged":[[0,0,1,0],[0,1,0,2]]}
["Going Concern and Liquidity (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Going Concern and Liquidity"," "," "," "]
["Net loss",{"v":44246,"d":"$ 44,246"},{"v":49606,"d":"$ 49,606"}," "]
["Cash",{"v":40082,"d":"40,082 "}," ",{"v":38816,"d":"$ 38,816"}]
["Capital deficiency",{"v":-315600,"d":"$ (315,600)"}," "," "]

{"sheet":"Significant Accounting Polici_3","index":33,"n_rows":4,"n_cols":3,"rows_kept":4}
["Significant Accounting Policies - Consolidation, Cash and Restricted Cash (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Cash and Restricted Cash"," "," "]
["Unrestricted",{"v":40082,"d":"$ 40,082"},{"v":38816,"d":"$ 38,816"}]
["Restricted",{"v":1211,"d":"$ 1,211"},{"v":5286,"d":"$ 5,286"}]

{"sheet":"Significant Accounting Polici_4","index":34,"n_rows":35,"n_cols":3,"rows_kept":35,"merged":[[0,0,1,0],[0,1,0,2]]}
["Significant Accounting Policies - Revenue Recognition (Details) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 USD ($) customer","Mar. 31, 2024 USD ($)"]
["Significant Accounting Policies"," "," "]
["Revenue",{"v":373225,"d":"$ 373,225"},{"v":388488,"d":"$ 388,488"}]
["Number of customers (customer) | customer",{"v":5,"d":"5 "}," "]
["Capitated Revenue [Member]"," "," "]
["Significant Accounting Policies"," "," "]
["Revenue",{"v":369517,"d":"$ 369,517"},{"v":384134,"d":"$ 384,134"}]
["Capitated Revenue [Member] | Revenue | Product Concentration Risk"," "," "]
["Significant Accounting Policies"," "," "]
["Percentage of total revenue (as a percent)",{"v":0.99,"d":"99%"},{"v":0.989,"d":"98.90%"}]
["Health Care, Other [Member]"," "," "]
["Significant Accounting Policies"," "," "]
["Revenue",{"v":3708,"d":"$ 3,708"},{"v":4354,"d":"$ 4,354"}]
["Health Care, Other [Member] | Revenue | Product Concentration Risk"," "," "]
["Significant Accounting Policies"," "," "]
["Percentage of total revenue (as a percent)",{"v":0.01,"d":"1%"},{"v":0.011,"d":"1.10%"}]
["Health Care Clinical Fees Insurance Revenue [Member]"," "," "]
["Significant Accounting Policies"," "," "]
["Revenue",{"v":992,"d":"$ 992"},{"v":1945,"d":"$ 1,945"}]
["Health Care Clinical Fees Insurance Revenue [Member] | Revenue | Product Concentration Risk"," "," "]
["Significant Accounting Policies"," "," "]
["Percentage of total revenue (as a percent)",{"v":0.003,"d":"0.30%"},{"v":0.005,"d":"0.50%"}]
["Health Care Coordination Management Fees [Member]"," "," "]
["Significant Accounting Policies"," "," "]
["Revenue",{"v":2695,"d":"$ 2,695"},{"v":2390,"d":"$ 2,390"}]
["Health Care Coordination Management Fees [Member] | Revenue | Product Concentration Risk"," "," "]
["Significant Accounting Policies"," "," "]
["Percentage of total revenue (as a percent)",{"v":0.007,"d":"0.70%"},{"v":0.006,"d":"0.60%"}]
["Health Care Incentive Fees [Member]"," "," "]
["Significant Accounting Policies"," "," "]
["Revenue",{"v":21,"d":"$ 21"},{"v":19,"d":"$ 19"}]
["Health Care Incentive Fees [Member] | Revenue | Product Concentration Risk"," "," "]
["Significant Accounting Policies"," "," "]
["Percentage of total revenue (as a percent)",{"v":0,"d":"0%"},{"v":0,"d":"0%"}]

{"sheet":"Significant Accounting Polici_5","index":35,"n_rows":21,"n_cols":4,"rows_kept":21,"merged":[[0,0,1,0]]}
["Significant Accounting Policies - Narratives (Details)",null,"3 Months Ended","12 Months Ended"]
[null,"Apr. 11, 2025 $ / shares","Mar. 31, 2025 customer $ / shares","Dec. 31, 2024 $ / shares"]
["Concentration Risk"," "," "," "]
["Number of customers (customer) | customer"," ",{"v":5,"d":"5 "}," "]
["Class A Common Stock"," "," "," "]
["Concentration Risk"," "," "," "]
["Common stock, par value (in dollars per share)"," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Class V Common Stock"," "," "," "]
["Concentration Risk"," "," "," "]
["Common stock, par value (in dollars per share)"," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Subsequent Event | Class A Common Stock"," "," "," "]
["Concentration Risk"," "," "," "]
["Reverse stock split (percent)",0.02," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Subsequent Event | Class V Common Stock"," "," "," "]
["Concentration Risk"," "," "," "]
["Reverse stock split (percent)",0.02," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Four Health Plan Customer | Revenue | Customer Concentration"," "," "," "]
["Concentration Risk"," "," "," "]
["Percentage of total revenue (as a percent)"," ",{"v":0.75,"d":"75%"},{"v":0.61,"d":"61%"}]

{"sheet":"Significant Accounting Polici_6","index":36,"n_rows":8,"n_cols":4,"rows_kept":8,"merged":[[0,0,1,0],[0,1,0,2]]}
["Significant Accounting Policies - Capitated Revenue (Details) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 USD ($) customer","Mar. 31, 2024 USD ($)","Dec. 31, 2024 customer"]
["Significant Accounting Policies"," "," "," "]
["Number of health plan customers | customer",{"v":3,"d":"3 "}," ",{"v":3,"d":"3 "}]
["TOTAL OPERATING REVENUE",{"v":373225,"d":"$ 373,225"},{"v":388488,"d":"$ 388,488"}," "]
["Capitated Revenue [Member]"," "," "," "]
["Significant Accounting Policies"," "," "," "]
["TOTAL OPERATING REVENUE",{"v":369517,"d":"$ 369,517"},{"v":384134,"d":"$ 384,134"}," "]

{"sheet":"Significant Accounting Polici_7","index":37,"n_rows":3,"n_cols":3,"rows_kept":3}
["Significant Accounting Policies - PDR (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Premium Deficiency Reserve (\"PDR\")"," "," "]
["Premium deficiency reserve",{"v":60406,"d":"$ 60,406"},{"v":67368,"d":"$ 67,368"}]

{"sheet":"Fair Value Measurements and H_3","index":38,"n_rows":12,"n_cols":3,"rows_kept":12}
["Fair Value Measurements and Hierarchy - Fair value Hierarchy for Financial Liabilities (Details) - Recurring - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis"," "," "]
["Warrant liability",{"v":6990,"d":"$ 6,990"},{"v":10312,"d":"$ 10,312"}]
["Level 1"," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis"," "," "]
["Warrant liability",{"v":127,"d":"127 "},{"v":127,"d":"127 "}]
["Level 2"," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis"," "," "]
["Warrant liability",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Level 3"," "," "]
["Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis"," "," "]
["Warrant liability",{"v":6863,"d":"$ 6,863"},{"v":10185,"d":"$ 10,185"}]

{"sheet":"Fair Value Measurements and H_4","index":39,"n_rows":13,"n_cols":3,"rows_kept":13}
["Fair Value Measurements and Hierarchy - Fair Value Measurement Inputs and Valuation Techniques (Details) - Private Placement Warrants - Level 3","Mar. 31, 2025 yr $ / shares","Dec. 31, 2024 yr $ / shares"]
["Volatility"," "," "]
["Warrants"," "," "]
["Warrants, measurement input",0.935,0.917]
["Risk-free interest rate"," "," "]
["Warrants"," "," "]
["Warrants, measurement input",{"v":0.04,"d":"0.040"},0.044]
["Exercise price"," "," "]
["Warrants"," "," "]
["Warrants, measurement input | $ / shares",{"v":0.5,"d":"0.50"},{"v":0.5,"d":"0.50"}]
["Expected term"," "," "]
["Warrants"," "," "]
["Warrants, measurement input | yr",{"v":6,"d":"6 "},6.2]

{"sheet":"Fair Value Measurements and H_5","index":40,"n_rows":15,"n_cols":3,"rows_kept":15,"merged":[[0,0,1,0],[0,1,0,2]]}
["Fair Value Measurements and Hierarchy - Changes in Fair Value (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"," "," "]
["Ending balance",{"v":6863,"d":"$ 6,863"},{"v":24,"d":"$ 24"}]
["Gain from change in fair value of warrant liability",{"v":-3322,"d":"(3,322)"},{"v":-216,"d":"(216)"}]
["Private Placement Warrants"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"," "," "]
["Beginning balance",{"v":10185,"d":"10,185 "},{"v":29,"d":"29 "}]
["Mark-to-market adjustment of stock warrants",{"v":-3322,"d":"$ (3,322)"},{"v":-5,"d":"$ (5)"}]
["Private Placement Warrants | Level 3"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"," "," "]
["Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]","Expense","Expense"]
["Public Warrants"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"," "," "]
["Gain from change in fair value of warrant liability",{"v":3300,"d":"$ 3,300"},{"v":200,"d":"$ 200"}]

{"sheet":"Property and Equipment - Schedu","index":41,"n_rows":28,"n_cols":4,"rows_kept":28,"merged":[[0,0,1,0],[0,1,0,2]]}
["Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":12579,"d":"$ 12,579"}," ",{"v":12582,"d":"$ 12,582"}]
["Less: accumulated depreciation",{"v":-7271,"d":"(7,271)"}," ",{"v":-6848,"d":"(6,848)"}]
["Property and equipment, net",{"v":5308,"d":"5,308 "}," ",{"v":5734,"d":"5,734 "}]
["Depreciation",{"v":600,"d":"600 "},{"v":500,"d":"$ 500"}," "]
["Leasehold improvements"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":2391,"d":"2,391 "}," ",{"v":2332,"d":"2,332 "}]
["Furniture & fixtures"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":1066,"d":"1,066 "}," ",{"v":1106,"d":"1,106 "}]
["Computer equipment & software"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":7064,"d":"7,064 "}," ",{"v":7060,"d":"7,060 "}]
["Medical equipment"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":1050,"d":"1,050 "}," ",{"v":1082,"d":"1,082 "}]
["Software (development in process)"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":343,"d":"343 "}," ",{"v":343,"d":"343 "}]
["Vehicles"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":633,"d":"633 "}," ",{"v":659,"d":"659 "}]
["Other"," "," "," "]
["Property and Equipment"," "," "," "]
["Property and equipment, gross",{"v":32,"d":"$ 32"}," ",{"v":0,"d":"$ 0"}]

{"sheet":"Property and Equipment - Narrat","index":42,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Property and Equipment - Narratives (Details) - USD ($) $ in Millions","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Property, Plant and Equipment [Abstract]"," "," "]
["Depreciation",{"v":0.6,"d":"$ 0.6"},{"v":0.5,"d":"$ 0.5"}]

{"sheet":"Property and Equipment - Assets","index":43,"n_rows":17,"n_cols":3,"rows_kept":17}
["Property and Equipment - Assets held For Sale (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Assets:"," "," "]
["Total assets",{"v":403,"d":"$ 403"},{"v":403,"d":"$ 403"}]
["Liabilities:"," "," "]
["Total liabilities",{"v":353,"d":"353 "},{"v":353,"d":"353 "}]
["Assets held for sale"," "," "]
["Assets:"," "," "]
["Property and equipment, net",{"v":571,"d":"571 "},{"v":571,"d":"571 "}]
["Intangible assets, net",{"v":7576,"d":"7,576 "},{"v":7576,"d":"7,576 "}]
["Other long-term assets",{"v":314,"d":"314 "},{"v":314,"d":"314 "}]
["Impairment of assets held for sale",{"v":8058,"d":"8,058 "},{"v":8058,"d":"8,058 "}]
["Total assets",{"v":403,"d":"403 "},{"v":403,"d":"403 "}]
["Liabilities:"," "," "]
["Accrued expenses and other current liabilities",{"v":56,"d":"56 "},{"v":56,"d":"56 "}]
["Operating lease liability",{"v":297,"d":"297 "},{"v":297,"d":"297 "}]
["Total liabilities",{"v":353,"d":"353 "},{"v":353,"d":"353 "}]
["Net assets",{"v":50,"d":"$ 50"},{"v":50,"d":"$ 50"}]

{"sheet":"Intangible Assets - Schedule of","index":44,"n_rows":29,"n_cols":3,"rows_kept":29}
["Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Definite lived intangible assets:"," "," "]
["Accumulated Amortization",{"v":-276699,"d":"$ (276,699)"},{"v":-256238,"d":"$ (256,238)"}]
["Intangible Assets, Net (Excluding Goodwill) [Abstract]"," "," "]
["Intangible assets, gross (excluding goodwill)",{"v":830588,"d":"830,588 "},{"v":830588,"d":"830,588 "}]
["Intangible assets, net",{"v":553889,"d":"553,889 "},{"v":574350,"d":"574,350 "}]
["Customer relationships"," "," "]
["Definite lived intangible assets:"," "," "]
["Gross Carrying Amount",{"v":671819,"d":"671,819 "},{"v":671819,"d":"671,819 "}]
["Accumulated Amortization",{"v":-223553,"d":"(223,553)"},{"v":-206951,"d":"(206,951)"}]
["Net Carrying Amount",{"v":448266,"d":"448,266 "},{"v":464868,"d":"464,868 "}]
["Trademarks"," "," "]
["Definite lived intangible assets:"," "," "]
["Gross Carrying Amount",{"v":148635,"d":"148,635 "},{"v":148635,"d":"148,635 "}]
["Accumulated Amortization",{"v":-50051,"d":"(50,051)"},{"v":-46427,"d":"(46,427)"}]
["Net Carrying Amount",{"v":98584,"d":"98,584 "},{"v":102208,"d":"102,208 "}]
["Payor contracts"," "," "]
["Definite lived intangible assets:"," "," "]
["Gross Carrying Amount",{"v":4700,"d":"4,700 "},{"v":4700,"d":"4,700 "}]
["Accumulated Amortization",{"v":-1528,"d":"(1,528)"},{"v":-1410,"d":"(1,410)"}]
["Net Carrying Amount",{"v":3172,"d":"3,172 "},{"v":3290,"d":"3,290 "}]
["Provider network"," "," "]
["Definite lived intangible assets:"," "," "]
["Gross Carrying Amount",{"v":4734,"d":"4,734 "},{"v":4734,"d":"4,734 "}]
["Accumulated Amortization",{"v":-1567,"d":"(1,567)"},{"v":-1450,"d":"(1,450)"}]
["Net Carrying Amount",{"v":3167,"d":"3,167 "},{"v":3284,"d":"3,284 "}]
["Medical licenses"," "," "]
["Indefinite lived intangible assets:"," "," "]
["Indefinite-lived intangible assets",{"v":700,"d":"$ 700"},{"v":700,"d":"$ 700"}]

{"sheet":"Intangible Assets - Narrative (","index":45,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Intangible Assets - Narrative (Details) - USD ($) $ in Millions","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Intangible Assets"," "," "]
["Amortization of intangible assets",{"v":20.5,"d":"$ 20.5"},{"v":21,"d":"$ 21"}]

{"sheet":"Debt (Details)","index":46,"n_rows":29,"n_cols":3,"rows_kept":29}
["Debt (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Debt"," "," "]
["Long-term debt, gross",{"v":199257,"d":"$ 199,257"},{"v":168807,"d":"$ 168,807"}]
["Less: unamortized debt issuance costs and original issue discount",{"v":-28136,"d":"(28,136)"},{"v":-13983,"d":"(13,983)"}]
["Long-term debt, net",{"v":171121,"d":"171,121 "},{"v":154824,"d":"154,824 "}]
["Current portion of long-term debt",{"v":-65000,"d":"(65,000)"},{"v":-65000,"d":"(65,000)"}]
["Long-term debt, net",{"v":106121,"d":"$ 106,121"},{"v":89824,"d":"89,824 "}]
["Repurchase Promissory Note Due June 2026 [Member]"," "," "]
["Debt"," "," "]
["Interest rate",{"v":0.11,"d":"11%"}," "]
["Long-term debt, gross",{"v":15000,"d":"$ 15,000"},{"v":15000,"d":"15,000 "}]
["Term loan facility, interest paid at 12.0%, due December 2025"," "," "]
["Debt"," "," "]
["Interest rate",{"v":0.12,"d":"12%"}," "]
["Long-term debt, gross",{"v":65000,"d":"$ 65,000"},{"v":65000,"d":"65,000 "}]
["VGS Promissory Note [Member]"," "," "]
["Debt"," "," "]
["Interest rate",{"v":0.135,"d":"13.50%"}," "]
["Long-term debt, gross",{"v":38057,"d":"$ 38,057"},{"v":38057,"d":"38,057 "}]
["VGS 2 Promissory Note"," "," "]
["Debt"," "," "]
["Long-term debt, gross",{"v":25375,"d":"25,375 "},{"v":25375,"d":"25,375 "}]
["VGS 3 Promissory Note"," "," "]
["Debt"," "," "]
["Long-term debt, gross",{"v":25375,"d":"25,375 "},{"v":25375,"d":"25,375 "}]
["VGS 4 Promissory Note"," "," "]
["Debt"," "," "]
["Long-term debt, gross",{"v":30450,"d":"30,450 "},{"v":0,"d":"$ 0"}]
["Less: unamortized debt issuance costs and original issue discount",{"v":-14200,"d":"$ (14,200)"}," "]

{"sheet":"Debt - Repurchase Promissory No","index":47,"n_rows":4,"n_cols":2,"rows_kept":4}
["Debt - Repurchase Promissory Note (Details)","Mar. 31, 2025"]
["Repurchase Promissory Note Due June 2026 [Member]"," "]
["Debt"," "]
["Interest rate",{"v":0.11,"d":"11%"}]

{"sheet":"Debt - Term Loan Facility (Deta","index":48,"n_rows":4,"n_cols":2,"rows_kept":4}
["Debt - Term Loan Facility (Details)","Mar. 31, 2025"]
["Term loan facility, interest paid at 12.0%, due December 2025"," "]
["Debt"," "]
["Interest rate",{"v":0.12,"d":"12%"}]

{"sheet":"Debt - VGS Promissory Note (Det","index":49,"n_rows":47,"n_cols":4,"rows_kept":47}
["Debt - VGS Promissory Note (Details)","Feb. 13, 2025 USD ($) shares $ / shares","Mar. 31, 2025 USD ($)","Dec. 31, 2024 USD ($)"]
["Debt"," "," "," "]
["Unamortized discount"," ",{"v":28136000,"d":"$ 28,136,000"},{"v":13983000,"d":"$ 13,983,000"}]
["VGS 4 Unsecured Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Debt Instrument, Convertible, Number of Equity Instruments | shares",{"v":1400000,"d":"1,400,000 "}," "," "]
["Debt Instrument, Convertible, Conversion Price | $ / shares",{"v":10.34,"d":"$ 10.34"}," "," "]
["Line of Credit | VGS 4 Unsecured Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Funding provided",{"v":30000000,"d":"$ 30,000,000"}," "," "]
["Percentage of upfront-fee",{"v":0.015,"d":"1.50%"}," "," "]
["Unamortized discount",{"v":14500000,"d":"$ 14,500,000"}," "," "]
["Warrants fair value",{"v":14000000,"d":"$ 14,000,000"}," "," "]
["Line of Credit | VGS 4 Unsecured Promissory Note [Member] | Option One"," "," "," "]
["Debt"," "," "," "]
["Paid in kind interest, percentage",{"v":0.115,"d":"11.50%"}," "," "]
["Paid in cash interest, percentage",{"v":0.08,"d":"8%"}," "," "]
["Line of Credit | VGS 4 Unsecured Promissory Note [Member] | Option Two"," "," "," "]
["Debt"," "," "," "]
["Paid in kind interest, percentage",{"v":0.195,"d":"19.50%"}," "," "]
["Line of Credit | VGS 4 Unsecured Promissory Note [Member] | First tranche"," "," "," "]
["Debt"," "," "," "]
["Funding provided",{"v":15000000,"d":"$ 15,000,000"}," "," "]
["Line of Credit | VGS 4 Unsecured Promissory Note [Member] | Second tranche"," "," "," "]
["Debt"," "," "," "]
["Funding provided",{"v":15000000,"d":"$ 15,000,000"}," "," "]
["Period Four | Line of Credit | VGS 4 Unsecured Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Debt Instrument, Back End Fee",{"v":0.09,"d":"9%"}," "," "]
["Period Three | Line of Credit | VGS 4 Unsecured Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Percentage of upfront-fee",{"v":0.0675,"d":"6.75%"}," "," "]
["Period One | Line of Credit | VGS 4 Unsecured Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Debt Instrument, Back End Fee",{"v":0.0225,"d":"2.25%"}," "," "]
["Period Two | Line of Credit | VGS 4 Unsecured Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Percentage of upfront-fee",{"v":0.045,"d":"4.50%"}," "," "]
["VGS Promissory Note [Member]"," "," "," "]
["Debt"," "," "," "]
["Interest rate"," ",{"v":0.135,"d":"13.50%"}," "]
["Term Loan Due December 2025 [Member]"," "," "," "]
["Debt"," "," "," "]
["Interest rate"," ",{"v":0.12,"d":"12%"}," "]
["VGS 4 Promissory Note"," "," "," "]
["Debt"," "," "," "]
["Unamortized discount"," ",{"v":14200000,"d":"$ 14,200,000"}," "]

{"sheet":"Debt - VGS Promissory Note (D_2","index":50,"n_rows":6,"n_cols":3,"rows_kept":6}
["Debt - VGS Promissory Note (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Debt"," "," "]
["Long-term debt, gross",{"v":199257,"d":"$ 199,257"},{"v":168807,"d":"$ 168,807"}]
["VGS 2 Promissory Note"," "," "]
["Debt"," "," "]
["Long-term debt, gross",{"v":25375,"d":"$ 25,375"},{"v":25375,"d":"$ 25,375"}]

{"sheet":"Net Loss per Share - Schedule o","index":51,"n_rows":20,"n_cols":3,"rows_kept":20,"merged":[[0,0,1,0],[0,1,0,2]]}
["Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Denominator–basic:"," "," "]
["Weighted average Class A common shares outstanding–basic (in shares)",{"v":3260,"d":"3,260 "},{"v":2378,"d":"2,378 "}]
["Net loss per share attributable to Class A common stockholders–basic (in dollars per share)",{"v":-6.28,"d":"$ (6.28)"},{"v":-7.86,"d":"$ (7.86)"}]
["Weighted average shares outstanding–diluted (in shares)",{"v":3260,"d":"3,260 "},{"v":2378,"d":"2,378 "}]
["Net loss per share attributable to Class A common stockholders– diluted (in dollars per share)",{"v":-6.28,"d":"$ (6.28)"},{"v":-7.86,"d":"$ (7.86)"}]
["Class A Common Stock"," "," "]
["Numerator–basic:"," "," "]
["Net loss attributable to Class A common stockholders–basic",{"v":-20480,"d":"$ (20,480)"},{"v":-18700,"d":"$ (18,700)"}]
["Net loss attributable to Class A common stockholders–diluted",{"v":-20480,"d":"$ (20,480)"},{"v":-18700,"d":"$ (18,700)"}]
["Denominator–basic:"," "," "]
["Weighted average Class A common shares outstanding–basic (in shares)",{"v":3260,"d":"3,260 "},{"v":2378,"d":"2,378 "}]
["Net loss per share attributable to Class A common stockholders–basic (in dollars per share)",{"v":-6.28,"d":"$ (6.28)"},{"v":-7.86,"d":"$ (7.86)"}]
["Net loss per share attributable to Class A common stockholders– diluted (in dollars per share)",{"v":-6.28,"d":"$ (6.28)"},{"v":-7.86,"d":"$ (7.86)"}]
["Class V Common Stock"," "," "]
["Numerator–basic:"," "," "]
["Shares of Class V common stock",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]
["Denominator–basic:"," "," "]
["Shares of Class V common stock (in shares)",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]

{"sheet":"Net Loss per Share - Schedule_2","index":52,"n_rows":16,"n_cols":3,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2]]}
["Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded from the Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Antidilutive Securities Excluded from Computation of Earnings Per Share"," "," "]
["Potentially dilutive securities excluded from the computation of diluted net loss per share (in shares)",{"v":10851,"d":"10,851 "},{"v":5773,"d":"5,773 "}]
["Stock warrants"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share"," "," "]
["Potentially dilutive securities excluded from the computation of diluted net loss per share (in shares)",{"v":6358,"d":"6,358 "},{"v":1639,"d":"1,639 "}]
["Stock options"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share"," "," "]
["Potentially dilutive securities excluded from the computation of diluted net loss per share (in shares)",{"v":433,"d":"433 "},{"v":111,"d":"111 "}]
["RSUs"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share"," "," "]
["Potentially dilutive securities excluded from the computation of diluted net loss per share (in shares)",{"v":141,"d":"141 "},{"v":93,"d":"93 "}]
["Shares of Class V common stock"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share"," "," "]
["Potentially dilutive securities excluded from the computation of diluted net loss per share (in shares)",{"v":3919,"d":"3,919 "},{"v":3930,"d":"3,930 "}]

{"sheet":"Redeemable Non-controlling In_3","index":53,"n_rows":12,"n_cols":3,"rows_kept":12}
["Redeemable Non-controlling Interest - Ownership of Common Units (Details) - shares shares in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["P3 Health Group, LLC"," "," "]
["Noncontrolling Interest"," "," "]
["Common unit outstanding (in shares)",{"v":7182,"d":"7,182 "},{"v":7176,"d":"7,176 "}]
["P3 Health Group, LLC"," "," "]
["Noncontrolling Interest"," "," "]
["Common unit outstanding (in shares)",{"v":3263,"d":"3,263 "},{"v":3257,"d":"3,257 "}]
["Non-controlling interests, ownership percentage by noncontrolling owners (as a percent)",{"v":0.454,"d":"45.40%"},{"v":0.454,"d":"45.40%"}]
["P3 Health Group, LLC | Non Controlling Interest Holders"," "," "]
["Noncontrolling Interest"," "," "]
["Common unit outstanding (in shares)",{"v":3919,"d":"3,919 "},{"v":3919,"d":"3,919 "}]
["Non-controlling interests, ownership percentage by noncontrolling owners (as a percent)",{"v":0.546,"d":"54.60%"},{"v":0.546,"d":"54.60%"}]

{"sheet":"Redeemable Non-controlling In_4","index":54,"n_rows":11,"n_cols":4,"rows_kept":11,"merged":[[0,0,1,0],[0,1,0,2]]}
["Redeemable Non-controlling Interest - Narrative (Details) - USD ($) $ in Millions","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Noncontrolling Interest"," "," "," "]
["Re-measurement adjustment recorded against fair value of redeemable noncontrolling interest",{"v":0,"d":"$ 0"},{"v":20.6,"d":"$ 20.6"}," "]
["Common unit exchange or redemption (in shares)",{"v":0,"d":"0 "},{"v":1500,"d":"1,500 "}," "]
["P3 Health Group, LLC"," "," "," "]
["Noncontrolling Interest"," "," "," "]
["Non-controlling interests, ownership percentage by noncontrolling owners (as a percent)",{"v":0.454,"d":"45.40%"}," ",{"v":0.454,"d":"45.40%"}]
["P3 Health Group, LLC | Non Controlling Interest Holders"," "," "," "]
["Noncontrolling Interest"," "," "," "]
["Non-controlling interests, ownership percentage by noncontrolling owners (as a percent)",{"v":0.546,"d":"54.60%"}," ",{"v":0.546,"d":"54.60%"}]

{"sheet":"Segment Reporting (Details)","index":55,"n_rows":25,"n_cols":5,"rows_kept":25,"merged":[[0,0,1,1],[0,2,0,3],[23,0,23,3],[24,0,24,3]]}
["Segment Reporting (Details) $ in Thousands",null,"3 Months Ended"]
[null,null,"Mar. 31, 2025 USD ($) segment","Mar. 31, 2024 USD ($)","Dec. 31, 2024 USD ($)"]
["Segment Reporting [Abstract]",null," "," "," "]
["Number of reportable segments (segment) | segment",null,{"v":1,"d":"1 "}," "," "]
["Segment Reporting Information [Line Items]",null," "," "," "]
["Medical expense",null,{"v":-372043,"d":"$ (372,043)"},{"v":-382057,"d":"$ (382,057)"}," "]
["Total",null,{"v":-43173,"d":"(43,173)"},{"v":-47534,"d":"(47,534)"}," "]
["Tax benefit",null,{"v":-1073,"d":"(1,073)"},{"v":-2072,"d":"(2,072)"}," "]
["Net loss",null,{"v":-44246,"d":"(44,246)"},{"v":-49606,"d":"(49,606)"}," "]
["TOTAL ASSETS","[1]",{"v":783870,"d":"783,870 "}," ",{"v":783420,"d":"$ 783,420"}]
["Single Reportable Segment [Member]",null," "," "," "]
["Segment Reporting Information [Line Items]",null," "," "," "]
["Revenue from Contract with Customer, Including Assessed Tax",null,{"v":373225,"d":"373,225 "},{"v":388488,"d":"388,488 "}," "]
["Medical expense",null,{"v":-352317,"d":"(352,317)"},{"v":-347582,"d":"(347,582)"}," "]
["Depreciation, Depletion and Amortization",null,{"v":-21052,"d":"(21,052)"},{"v":-21539,"d":"(21,539)"}," "]
["Other Cost and Expense, Operating",null,{"v":-14900,"d":"(14,900)"},{"v":-28561,"d":"(28,561)"}," "]
["Interest Expense, Operating",null,{"v":-8725,"d":"(8,725)"},{"v":-4256,"d":"(4,256)"}," "]
["Interest Income, Operating",null,{"v":322,"d":"322 "},{"v":391,"d":"391 "}," "]
["Total",null,{"v":-43173,"d":"(43,173)"},{"v":-47534,"d":"(47,534)"}," "]
["Tax benefit",null,{"v":-1073,"d":"(1,073)"},{"v":-2072,"d":"(2,072)"}," "]
["Net loss",null,{"v":-44246,"d":"(44,246)"},{"v":-49606,"d":"(49,606)"}," "]
["TOTAL ASSETS",null,{"v":129350,"d":"129,350 "}," ",{"v":121266,"d":"$ 121,266"}]
["Other Medical Expenses",null,{"v":-19726,"d":"$ (19,726)"},{"v":-34475,"d":"$ (34,475)"}," "]
[]
["[1] The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 13 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC’s consolidated VIEs totaling $10.7 million and $9.3 million as of March 31, 2025 and December 31, 2024, respectively, and total liabilities of P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $15.6 million and $14.9 million as of March 31, 2025 and December 31, 2024, respectively. These VIE assets and liabilities do not include $41.1 million and $40.3 million of net amounts due to affiliates as of March 31, 2025 and December 31, 2024, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets."]

{"sheet":"Capitalization - Reverse Stock ","index":56,"n_rows":19,"n_cols":4,"rows_kept":19}
["Capitalization - Reverse Stock Split (Details)","Apr. 11, 2025 $ / shares shares","Mar. 31, 2025 $ / shares","Dec. 31, 2024 $ / shares"]
["Class A Common Stock"," "," "," "]
["Share Repurchase Program [Line Items]"," "," "," "]
["Common stock, par value (in dollars per share) | $ / shares"," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Class A Common Stock | Subsequent Event"," "," "," "]
["Share Repurchase Program [Line Items]"," "," "," "]
["Common stock, par value (in dollars per share) | $ / shares",{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Stock Issued During Period, Shares, Reverse Stock Splits | shares",{"v":163159548,"d":"163,159,548 "}," "," "]
["Reverse stock split (percent)",0.02," "," "]
["Stock Issued During Period, Shares, Stock Splits | shares",{"v":3263093,"d":"3,263,093 "}," "," "]
["Class V Common Stock"," "," "," "]
["Share Repurchase Program [Line Items]"," "," "," "]
["Common stock, par value (in dollars per share) | $ / shares"," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Class V Common Stock | Subsequent Event"," "," "," "]
["Share Repurchase Program [Line Items]"," "," "," "]
["Common stock, par value (in dollars per share) | $ / shares",{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Stock Issued During Period, Shares, Reverse Stock Splits | shares",{"v":195956984,"d":"195,956,984 "}," "," "]
["Reverse stock split (percent)",0.02," "," "]
["Stock Issued During Period, Shares, Stock Splits | shares",{"v":3919124,"d":"3,919,124 "}," "," "]

{"sheet":"Variable Interest Entities - Na","index":57,"n_rows":4,"n_cols":2,"rows_kept":4}
["Variable Interest Entities - Narratives (Details)","Mar. 31, 2025"]
["Variable Interest Entities"," "]
["Management service fee (as a percent)",{"v":0.02,"d":"2%"}]
["Investment, Variable Interest Rate, Type [Extensible Enumeration]","Prime Rate [Member]"]

{"sheet":"Variable Interest Entities - Ba","index":58,"n_rows":45,"n_cols":5,"rows_kept":45,"merged":[[0,0,1,1],[0,2,0,3],[43,0,43,3],[44,0,44,3]]}
["Variable Interest Entities - Balance Sheet (Details) - USD ($) $ in Thousands",null,"3 Months Ended"]
[null,null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["ASSETS",null," "," "," "]
["Cash",null,{"v":40082,"d":"$ 40,082"}," ",{"v":38816,"d":"$ 38,816"}]
["Health plan receivable",null,{"v":129350,"d":"129,350 "}," ",{"v":121266,"d":"121,266 "}]
["Prepaid expenses and other current assets",null,{"v":14980,"d":"14,980 "}," ",{"v":14422,"d":"14,422 "}]
["Property and equipment, net",null,{"v":5308,"d":"5,308 "}," ",{"v":5734,"d":"5,734 "}]
["Other long-term assets",null,{"v":33238,"d":"33,238 "}," ",{"v":19196,"d":"19,196 "}]
["TOTAL ASSETS","[1]",{"v":783870,"d":"783,870 "}," ",{"v":783420,"d":"783,420 "}]
["LIABILITIES AND MEMBERS’ DEFICIT",null," "," "," "]
["Accounts payable",null,{"v":11503,"d":"11,503 "}," ",{"v":8442,"d":"8,442 "}]
["Accrued expenses and other current liabilities",null,{"v":27971,"d":"27,971 "}," ",{"v":29416,"d":"29,416 "}]
["Accrued payroll",null,{"v":3216,"d":"3,216 "}," ",{"v":2722,"d":"2,722 "}]
["Claims payable",null,{"v":268664,"d":"268,664 "}," ",{"v":255089,"d":"255,089 "}]
["Other long-term liabilities",null,{"v":31665,"d":"31,665 "}," ",{"v":26001,"d":"26,001 "}]
["TOTAL LIABILITIES","[1]",{"v":662791,"d":"662,791 "}," ",{"v":633891,"d":"633,891 "}]
["TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY",null,{"v":783870,"d":"$ 783,870"}," ",{"v":783420,"d":"$ 783,420"}]
["Accounts Payable, Noncurrent, Related Party [Extensible Enumeration]",null,"Affiliated Entity [Member]"," ","Affiliated Entity [Member]"]
["TOTAL OPERATING REVENUE",null,{"v":373225,"d":"$ 373,225"},{"v":388488,"d":"$ 388,488"}," "]
["Expense",null,{"v":411313,"d":"411,313 "},{"v":432319,"d":"432,319 "}," "]
["Net loss",null,{"v":-44246,"d":"(44,246)"},{"v":-49606,"d":"(49,606)"}," "]
["VIE",null," "," "," "]
["ASSETS",null," "," "," "]
["Cash",null,{"v":5093,"d":"5,093 "}," ",{"v":5216,"d":"$ 5,216"}]
["Clinic fees, insurance and other receivable",null,{"v":3012,"d":"3,012 "}," ",{"v":2440,"d":"2,440 "}]
["Health plan receivable",null,{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}]
["Prepaid expenses and other current assets",null,{"v":450,"d":"450 "}," ",{"v":447,"d":"447 "}]
["Property and equipment, net",null,{"v":32,"d":"32 "}," ",{"v":37,"d":"37 "}]
["Other long-term assets",null,{"v":2075,"d":"2,075 "}," ",{"v":1116,"d":"1,116 "}]
["TOTAL ASSETS",null,{"v":10662,"d":"10,662 "}," ",{"v":9256,"d":"9,256 "}]
["LIABILITIES AND MEMBERS’ DEFICIT",null," "," "," "]
["Accounts payable",null,{"v":4319,"d":"4,319 "}," ",{"v":4521,"d":"4,521 "}]
["Accrued expenses and other current liabilities",null,{"v":1685,"d":"1,685 "}," ",{"v":677,"d":"677 "}]
["Accrued payroll",null,{"v":4338,"d":"4,338 "}," ",{"v":3795,"d":"3,795 "}]
["Claims payable",null,{"v":4456,"d":"4,456 "}," ",{"v":5004,"d":"5,004 "}]
["Other long-term liabilities",null,{"v":840,"d":"840 "}," ",{"v":919,"d":"919 "}]
["Due to consolidated entities of P3",null,{"v":41070,"d":"41,070 "}," ",{"v":40264,"d":"40,264 "}]
["TOTAL LIABILITIES",null,{"v":56708,"d":"56,708 "}," ",{"v":55180,"d":"55,180 "}]
["MEMBERS’ DEFICIT",null,{"v":-46046,"d":"(46,046)"}," ",{"v":-45924,"d":"(45,924)"}]
["TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY",null,{"v":10662,"d":"10,662 "}," ",{"v":9256,"d":"$ 9,256"}]
["TOTAL OPERATING REVENUE",null,{"v":8159,"d":"8,159 "},{"v":9764,"d":"9,764 "}," "]
["Expense",null,{"v":8154,"d":"8,154 "},{"v":9897,"d":"9,897 "}," "]
["Net loss",null,{"v":5,"d":"$ 5"},{"v":-133,"d":"$ (133)"}," "]
[]
["[1] The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 13 “Variable Interest Entities,” P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC’s consolidated VIEs totaling $10.7 million and $9.3 million as of March 31, 2025 and December 31, 2024, respectively, and total liabilities of P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $15.6 million and $14.9 million as of March 31, 2025 and December 31, 2024, respectively. These VIE assets and liabilities do not include $41.1 million and $40.3 million of net amounts due to affiliates as of March 31, 2025 and December 31, 2024, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets."]

{"sheet":"Variable Interest Entities - In","index":59,"n_rows":11,"n_cols":3,"rows_kept":11,"merged":[[0,0,1,0],[0,1,0,2]]}
["Variable Interest Entities - Income Statement (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Variable Interest Entity"," "," "]
["Revenue",{"v":373225,"d":"$ 373,225"},{"v":388488,"d":"$ 388,488"}]
["Expense",{"v":411313,"d":"411,313 "},{"v":432319,"d":"432,319 "}]
["Net loss",{"v":-44246,"d":"(44,246)"},{"v":-49606,"d":"(49,606)"}]
["VIE"," "," "]
["Variable Interest Entity"," "," "]
["Revenue",{"v":8159,"d":"8,159 "},{"v":9764,"d":"9,764 "}]
["Expense",{"v":8154,"d":"8,154 "},{"v":9897,"d":"9,897 "}]
["Net loss",{"v":5,"d":"$ 5"},{"v":-133,"d":"$ (133)"}]

{"sheet":"Income Taxes- Components of Los","index":60,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes- Components of Loss Before Taxes (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Income Tax Disclosure [Abstract]"," "," "]
["LOSS BEFORE INCOME TAXES",{"v":-43173,"d":"$ (43,173)"},{"v":-47534,"d":"$ (47,534)"}]

{"sheet":"Income Taxes- Components of inc","index":61,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes- Components of income tax expense (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Deferred income taxes:"," "," "]
["Total income tax expense",{"v":1073,"d":"$ 1,073"},{"v":2072,"d":"$ 2,072"}]

{"sheet":"Income Taxes - Reconciliation o","index":62,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Reconciliation of income tax provision (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Income Tax Disclosure [Abstract]"," "," "]
["Total income tax expense",{"v":1073,"d":"$ 1,073"},{"v":2072,"d":"$ 2,072"}]

{"sheet":"Income Taxes - Narrative (Detai","index":63,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Income Taxes - Narrative (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Income Taxes"," "," "]
["Tax benefit",{"v":1073,"d":"$ 1,073"},{"v":2072,"d":"$ 2,072"}]

{"sheet":"Subsequent Events (Details)","index":64,"n_rows":18,"n_cols":5,"rows_kept":18}
["Subsequent Events (Details) $ / shares in Units, $ in Millions","May 01, 2025 USD ($)","Apr. 11, 2025 $ / shares","Mar. 31, 2025 $ / shares","Dec. 31, 2024 $ / shares"]
["Class A Common Stock"," "," "," "," "]
["Subsequent Events"," "," "," "," "]
["Common stock, par value (in dollars per share)"," "," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Class V Common Stock"," "," "," "," "]
["Subsequent Events"," "," "," "," "]
["Common stock, par value (in dollars per share)"," "," ",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Subsequent Event"," "," "," "," "]
["Subsequent Events"," "," "," "," "]
["Proceeds from divesture of business | $",{"v":0.1,"d":"$ 0.1"}," "," "," "]
["Subsequent Event | Class A Common Stock"," "," "," "," "]
["Subsequent Events"," "," "," "," "]
["Reverse stock split (percent)"," ",0.02," "," "]
["Common stock, par value (in dollars per share)"," ",{"v":0.0001,"d":"$ 0.0001"}," "," "]
["Subsequent Event | Class V Common Stock"," "," "," "," "]
["Subsequent Events"," "," "," "," "]
["Reverse stock split (percent)"," ",0.02," "," "]
["Common stock, par value (in dollars per share)"," ",{"v":0.0001,"d":"$ 0.0001"}," "," "]

{"sheet":"Warrants - Public and Private P","index":65,"n_rows":16,"n_cols":4,"rows_kept":16,"merged":[[0,0,1,0],[0,1,0,2]]}
["Warrants - Public and Private Placement Warrants (Details) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 USD ($) yr $ / shares","Mar. 31, 2024 USD ($)","Dec. 31, 2024 yr $ / shares"]
["Warrants"," "," "," "]
["Gain (loss) from change in fair value of warrant liability | $",{"v":-3322,"d":"$ (3,322)"},{"v":-216,"d":"$ (216)"}," "]
["Private Placement Warrants | Level 3 | Volatility"," "," "," "]
["Warrants"," "," "," "]
["Warrants, measurement input",0.935," ",0.917]
["Private Placement Warrants | Level 3 | Risk-free interest rate"," "," "," "]
["Warrants"," "," "," "]
["Warrants, measurement input",{"v":0.04,"d":"0.040"}," ",0.044]
["Private Placement Warrants | Level 3 | Exercise price"," "," "," "]
["Warrants"," "," "," "]
["Warrants, measurement input | $ / shares",{"v":0.5,"d":"0.50"}," ",{"v":0.5,"d":"0.50"}]
["Private Placement Warrants | Level 3 | Expected term"," "," "," "]
["Warrants"," "," "," "]
["Warrants, measurement input | yr",{"v":6,"d":"6 "}," ",6.2]

{"sheet":"Warrants (Details)","index":66,"n_rows":4,"n_cols":3,"rows_kept":4}
["Warrants (Details) - $ / shares","Mar. 31, 2025","Dec. 31, 2024"]
["Class A Common Stock"," "," "]
["Warrants"," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]

{"sheet":"Related Parties - Atrio Health ","index":67,"n_rows":14,"n_cols":4,"rows_kept":14,"merged":[[0,0,1,0],[0,1,0,2]]}
["Related Parties - Atrio Health Plans (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Related Parties"," "," "," "]
["Revenue",{"v":373225,"d":"$ 373,225"},{"v":388488,"d":"$ 388,488"}," "]
["Medical expense",{"v":372043,"d":"372,043 "},{"v":382057,"d":"382,057 "}," "]
["Health plan receivable",{"v":129350,"d":"129,350 "}," ",{"v":121266,"d":"$ 121,266"}]
["Claims payable",{"v":268664,"d":"268,664 "}," ",{"v":255089,"d":"255,089 "}]
["Health plan settlements payable",{"v":56715,"d":"56,715 "}," ",{"v":55565,"d":"$ 55,565"}]
["Capitated Revenue [Member]"," "," "," "]
["Related Parties"," "," "," "]
["Revenue",{"v":369517,"d":"369,517 "},{"v":384134,"d":"384,134 "}," "]
["Other patient service revenue"," "," "," "]
["Related Parties"," "," "," "]
["Revenue",{"v":3708,"d":"$ 3,708"},{"v":4354,"d":"$ 4,354"}," "]

{"sheet":"Related Parties - VGS Promissor","index":68,"n_rows":7,"n_cols":4,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Related Parties - VGS Promissory Note (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Related Parties"," "," "," "]
["Interest expense, net",{"v":8725,"d":"$ 8,725"},{"v":4256,"d":"$ 4,256"}," "]
["Long-term debt, net",{"v":106121,"d":"106,121 "}," ",{"v":89824,"d":"$ 89,824"}]
["Accrued interest",{"v":12410,"d":"12,410 "}," ",{"v":12460,"d":"12,460 "}]
["Accrued expenses",{"v":11503,"d":"$ 11,503"}," ",{"v":8442,"d":"$ 8,442"}]